Alzheimer's and you.

Long-term care for Alzheimer's

2012-01-17T10:53:00.000-08:00

There may come a time when it is too difficult for you to care for your loved one at home. As the disease progresses, your job will become increasingly difficult — despite a variety of community services — to the point where long-term residential care may be the most responsible option.

Making the decision

As you come to terms with residential care, you may grapple with feelings of guilt that you're abandoning the person. You may assume incorrectly that people who wind up in nursing homes were discarded by their families. But the truth is just the opposite. Most families exhaust every other option before resorting to this type of arrangement, and, contrary to popular belief, most families do stay connected to the individual and visit often. You can also draw comfort in knowing that there are an increasing number of good programs that specialize in care and treatment of people with Alzheimer's disease.

Better understanding for Alzheimer's patient care

There has been a shift in the general philosophy of caring for people with dementia. In the past, the general consensus was that they should be continually oriented to reality. For instance, if a person talked about visiting a sister who had died, the caregiver would remind the person what year it was and that the relative wasn't alive. Experts recommended responses like "No, I'm not your daughter, I'm your nurse."

Experts now believe that these efforts are futile and only frustrate the individual. Today, the preferred approach is to validate the person's feelings. For instance, responses like "You must really love her" to a man who talks about his dead wife, rather than, "She died 8 years ago," fosters emotional well-being. Repeated validation may also curb some behavior problems associated with frustration.

Resurrecting the patients remove frustration

There is also more of an attempt to resurrect what's left of the person's "self." In high-quality programs, caregivers try to understand each person's past interests and plan activities accordingly. If, for example, a person loved to dance, he or she may still derive considerable enjoyment from music and dance activities at a center.

In one case involving someone who had been a newspaper reporter most of his life, his caregivers set up a makeshift newsroom with a typewriter and assigned him the task of writing a newsletter for the center. He was able to enjoy this until typing became too frustrating. Although his caregivers eventually removed the typewriter, they still reinforced the idea that he was working in a newsroom. In another case, a caregiver arranged for several former stamp collectors in the assisted-living facility to see a stamp exhibit that was in town. Despite their disease, the caregiver said they seemed to thoroughly enjoy the experience.

Real facts

Over half of all individuals living in nursing homes have Alzheimer's disease or another dementia.

Evaluating a home for Alzheimer's patient

Keep in mind that not all specialized Alzheimer's care is equal. When you visit a home, try to determine what makes it unique.For up to date information on the wide variety of options available and how to evaluate them because the Alzheimer's patient may live for as long as 4 to 8 years and during that time the patient will gets worse in a regressive state, contact the Mary Joseph Foundation.

Please remember these

When you visit a facility, ask plenty of questions, such as these:

How is the program geared specifically for people with Alzheimer's disease?
Are the caregivers trained in the treatment of Alzheimer's?
Is it a homelike environment?
Are residents engaged in meaningful activities?
Does the facility incorporates design features that can be helpful to those with Alzheimer's, such as enhanced lighting, color-coded hallways, and plenty of walking room?
Is the environment safe? How secure is it for people who wander?
How would an upset resident be handled?
How many people live there? What's the ratio of staff members to residents?
Can medical care be given on site if needed? Who provides it? Skilled nurses? Visiting physicians?
What personal items can the resident bring?
Are skilled professionals — including registered nurses, licensed practical nurses, and certified nursing assistants — on duty at all times?
How long and often may family members visit?
What's the cost? Does the facility requires you to pay privately?
If the patient needs to change to Medicaid funding after a few years, will he or she be able to remain at the facility?
Under what circumstances would a resident be required to leave?

Remember the average cost today of long-term care is between $46,860 a year for an assisted-living facility and $92,095 a year for a private room in a nursing home, you'll have to investigate payment options.
Remember we are here to help.

www.maryjosephfoundation.blogspot.com

www.marycharityfoundation.blogspot.com

Mary Joseph Foundation a non-profit organization for Alzheimer's disease.

Some famous people who died from Alzheimer’s disease

2012-01-16T06:34:00.000-08:00

In Alzheimer’s disease, memory for old events are preserved till the advanced stages of the disease. In the early stages, the ability to learn new things are impaired. Since the common man assumes that memory for old events are more important, some individuals who have Alzheimer's disease is not brought to the doctor in the early stages of the disease.

Even if a individual with changes in intellectual capability is taken to a doctor, general physicians with limited experience in treating Alzheimer’s disease will rarely make a specific diagnosis of this disease. Although awareness is increasing, many misconceptions prevail among medical practitioners.

Some famous people who died from Alzheimer’s disease

Adcock, Joe
baseball player

Astor Brooke

was an American philanthropist and socialite

Albertson, Mabel
actress

Andrews, Dana
actor

Balanchine, George
dancer, choreographer

Bing, Rudolph
opera impresario

Brooks, James
artist

Burrows, Abe
author

Chen, Joyce
chef

Copeland, Aaron
composer

DeKooning, Willem
artist

Dorsey, Thomas, A
father of gospel music

Fears, Tom
hall of fame professional football player and coach

Feraud, Louis
prominent fashion designer

Francis, Arlene
actress

Frankovich, Mike
movie producer

French, John Douglas
physician

Estelle Getty

actress

Goldwater, Barry
Arizona Senator

Heston Charlton

actor

Hayworth, Rita
actress

Henriquez, Raul Silva
Roman Catholic cardinal, human rights advocate

Joseph Mary

Mary Joseph Foundation

Klutznick, Philip
real estate developer, adviser to five U.S. Presidents

Leroy, Mervyn
director - 1987

Lord, Jack
actor

MacDonald, Ross
author

Meredith, Burgess
actor

Murdoch, Iris
author

O’Brien, Edmond
actor

O’Connell, Arthur
actor

Owen, Marv
baseball player

Picon, Molly
actress

Preminger, Otto
director

Quackenbush, Bill
hall of fame professional hockey player

Reagan, Ronald
former President of USA

Ritz, Harry
performer

Robinson, Sugar Ray
boxer

Rockwell, Norman
artist

Scott, Simon
actor

Shulman, Irving
screenwriter

Schwartz, Betty
first woman to win an Olympic gold medal in track events

Swift, Kay
composer

Van Vogt, Alfred
science fiction writer

White, E.B.
author

Wilson, Harold
British Prime Minister

Mary Joseph Foundation a non-profit international organization

Charlton Heston 1924-2008

Mary Joseph Foundation extends its deepest sympathies to the Heston family on the passing of Charlton Heston on Saturday, April 5. In 2002, Mr. Heston courageously announced to the public that he was suffering with symptoms consistent with Alzheimer’s disease.
Currently there are over 8 million Americans living with dementia/Alzheimer’s disease and that number is expected to grow to as many as 30 to 35 million by 2050. Alzheimer’s disease is the seventh leading cause of death in the United States and growing.
Researchers are close to developing accurate ways to diagnose and treat Alzheimer’s, but current Alzheimer's funding is nowhere near enough. Significantly increased federal funding for Alzheimer's research, education and care is imperative to reach the goal of a world without Alzheimer’s.

Estelle Getty Born: July 25, 1924 in New York City, New York Occupation: Actor: ... She played Sophia on Golden Girls from 1985 to 1992...We at the Mary Joseph Foundation are sorry to hear about Estelle Getty condition, for sometime now she had developed and been living with dementia and later coming down with Alzheimer's.

Brooke Astor (March 30, 1902 – August 13, 2007) was an American philanthropist and socialite who was the chairwoman of the Vincent Astor Foundation, in 2000 Brooke Astor was diagnosis by her doctor of having Alzheimer's disease...On August 13, 2007 she died from Alzheimer's.

Although there is no cure as yet for Alzheimer’s disease, a lot can be done to make the individuals with Alzheimer's disease more comfortable.

Learn more about Alzheimer:

www.marycharityfoundation.blogspot.com

Mary Joseph Foundation a non-profit organization for Alzheimer's disease.

2011-03-04T08:56:00.001-08:00

Excellence through Real-time

Today while many advances have been made in IT infrastructure, some IT departments still struggle to respond to increasing business demands yet hold the line on costs.

Companies are increasingly employing virtualization and automation to improve the flexibility and use of computing resources, but still struggle with over-provisioning and complexity. A shared services model enables IT to address these issues. Our dept knowledge and experience working with high performance servers describes an advanced blade server solution, with a focus on how the solution delivers shared IT infrastructure services — improving the speed and reliability of service delivery whiles increasing IT efficiency and lowering associated costs.

Due to the interconnectedness of systems, most business continuity efforts are rightly focused on safeguarding the availability of information and planning a response to potential disruptions. But in addition to preserving access to IT resources, corporations especially midsize businesses face increasingly stringent requirements for compliance. And while they need to effectively manage legal liability, they must also control costs.

Providing preemptive, cost-effective. end-to-end protection that stops external and internal security threats before they impact the business.

Ensuring the continuity of the business in the event of disaster, natural or man made.

Availability is the first requirement of a responsive and flexible infrastructure. Without adequate protection of IT resources from threats, and without dependable access to data and information to all businesses especially small to midsize businesses cannot stay in business, much less take advantage of opportunities.

In essence,these businesses strongly depend on their integrated business and IT infrastructures to keep employees productive and to meet customer demands. At the same time that these infrastructures have become highly interconnected, the threats to them have become more significant.

Creating a smarter infrastructure requires businesses to fully understand the evolving threats to their business and to develop strategies and deploy tools that minimize risk and maintain and improve service.

Our IT engineers along with IBM business continuity solutions help maintain continuity of service and support for all business clients IT systems and help ensure that normal business operations continue even when there is an unanticipated event or compromise to their environment. The solutions also help business clients address compliance requirements, enabling them to reduce risks to the business.

The business continuity requirements faced by midmarket business clients fall under three basic areas:

Creating and maintaining a highly available IT infrastructure: Ensuring that employees, partners and customers can access valuable data and applications by protecting them from disruptions that are planned and unplanned, natural and man-made.

Implementing and maintaining data backup and restore systems and processes: Using combinations of online, mirroring and tape storage systems to recover from disruptions.

Creating an archiving and data lifecycle approach that balances business and compliance demands: Having data, such as e-mails, meet regulatory or legal guidelines.

The challenge that all business clients face is balancing the need for meeting these requirements—and therefore minimizing risk—with cost considerations.

First all companies must fully understand the planning and deployment requirements of today's SaaS solution. Our engineers with IBM will describe the critical consulting and support services required to successfully select, deploy and fully utilize SaaS solutions to achieve your business objectives and safeguard your mission-critical applications and data.

Achieving Engineering Compliant Excellence through Real-time Performance Management and Continuous Improvement. Compliance management, integration, and data utilization are key issues to address in order to improve responsiveness and performance. Life Sciences manufacturers are feeling new pressure on their operations from many directions. Dynamic market needs, increased compliance requirements, more distributed manufacturing operations, rapid product innovation, lean manufacturing, and the approaching transition to new information technology all manifest themselves on the plant floor and throughout the enterprise - and often lead to pleas for new technology solutions.

One of the essential characteristics of a cloud architecture is the ability to pool resources. The provider's compute, network, and storage resources are pooled to serve multiple consumers using a multi-tenant model, with different physical and virtual resources dynamically assigned and reassigned according to consumer demand. There is a sense of location independence in that the customer generally has no control or knowledge over the exact location of the provided resources but may be able to specify location at a higher level of abstraction (e.g., country, state, or data center). Examples of resources include storage, processing, memory, network bandwidth, and virtual machines.

Each tenant subscribed to compute, network, and storage resources in a cloud is entitled to a given SLA. One tenant may have higher SLA requirements than another based on a business model or organizational hierarchy. For example, tenant A may have higher compute and network bandwidth requirements than tenant B, while tenant B may have a higher storage capacity requirement. The main design objective is to ensure that tenants within this environment properly receive subscribed SLA while their data, communication, and application environments are securely separated, protected, and isolated from other tenants.

One of the main differences between traditional shared hosting (internal or external) and a typical IaaS cloud service is the level of control available to the user. Traditional hosting services provide users with general application or platform administrative control, whereas IaaS deployments typically provide the user with broader control over the compute resources. The secure cloud architecture further extends user control end-to-end throughout the environment: the compute platform, the network connectivity, storage resources, and data management. This architecture enables service providers and enterprises to securely offer their users unprecedented control over their entire application environment. Unique isolation technologies combined with extensive management flexibility delivers all of the benefits of cloud computing for IT providers to confidently provide high levels of security and service for multi-tenant customer and consolidated application environments.

The IBM X-Force Factor difference

IBM ISS offers best-of-breed security solutions that protect key virtualization control points: network, endpoint, and server – all backed by the world-renowned IBM X-Force® research and development team. We deliver:

Integrated virtualization security products and services
Experts who can help you meet your virtualization security goals
Requirements planning, policy design, and implementation services

The world-renowned IBM X-Force research and development team provides the foundation for IBM ISS’ preemptive approach to Internet security. The X-Force team delivers a constant stream of security intelligence and data that IBM ISS customers can use to improve the security of their networks, servers, endpoints and data.

IBM X-Force is one of the most respected commercial security research groups in the world. This industry-leading team of security experts researches and evaluates vulnerabilities and security issues, develops assessment and countermeasure technology for IBM security solutions, and educates the public about emerging Internet threats.
Professional Security Services from IBM Security Services deliver comprehensive, enterprise-wide security assessment, design and deployment services to help you build effective information security solutions. Expert security consultants can show you how to implement network security best practices that can reduce online threats to your critical business assets.

Professional Security Services from the experts
IBM Security Services' security experts use proprietary toolsets and the latest security threat intelligence with advanced countermeasures to help you build effective security programs that enhance your business operations and improve your security posture. Our engineering consultants can help you:

Mitigate security threats to business operations
Proactively address security issues before they are exploited
Comply with regulatory guidelines
Lower operating costs through the consistent deployment of security policy and procedures
Provide secure extensions of business applications
Improve productivity by optimizing security efforts for efficient management and maintenance
Shorten implementation cycles for new security solution deployments and software updates
Limit the impact of security incidents with advanced preparation and incident response

•Availability allows the infrastructure to meet the expectation of compute, network, and storage to always be available even in the event of failure. Like the Secure Separation pillar, each layer has its own manner of providing a high availability configuration that works seamlessly with adjacent layers. Security and availability are best deployed from a layered approach.

•Secure Separation ensures one tenant does not have access to another tenant's resources, such as virtual machine, network bandwidth, and storage. Each tenant must be securely separated using techniques such as access control, VLAN segmentation, and virtual storage controllers. Also, each layer has its own means of enforcing policies that help reinforce the policies of the adjacent layers.

•Service Assurance provides isolated compute, network, and storage performance during both steady state and non-steady state. For example, the network can provide each tenant with a certain bandwidth guarantee using Quality of Service (QoS), resource pools within VMware help balance and guarantee CPU and memory resources, while FlexShare can balance resource contention across storage volumes.

The key to developing a robust design is clearly defining the requirements and applying a proven methodology and design principles.

202-241-2880

{Cisco. IBM. vmware partners}

2011-02-09T09:48:00.000-08:00

Power station, the future is here with us!

The smart grid promises a more efficient way of supplying and consuming energy. In essence, the smart grid is a data communications network integrated with the power grid that enables power grid operators to collect and analyze data about power generation, transmission, distribution, and consumption-all in near real time. Smart grid communication technology provides predictive information and recommendations to utilities, their suppliers, and their customers on how best to manage power.

To achieve this vision of ubiquitous near-real time information, a transformation of the power grid communications infrastructure is needed, particularly in transmission and distribution substations. While modern data communication has evolved from telephony modems to IP networks, many power utilities are still deploying modem access and serial bus technology to communicate with their substations. The existing supervisory control and data acquisition remote terminal unit systems located inside the substation cannot scale and evolve to support next-generation intelligence. Since flexible IEC 61850-compliant intelligent electronic devices and utility-grade rugged IP routers and Ethernet switches have become more widely available, many utilities are now ready to transform their communications networks from serial to IP-based communications.

Substation Automation Business Factors and Benefits...The transition from a legacy to future substation is taking place because of various substation automation factors:

• Reduce operations expense: The future substation reduces operational expenses by converging multiple control and monitoring systems onto a single IP network while helping ensure higher priority for grid operational and management traffic. This network convergence enables utility companies to reduce power outages and service interruptions as well as decrease response times by quickly identifying, isolating, diagnosing and repairing faults. These improvements are achieved through automation and flexible access to operational control systems and, in the future, through better data correlation across multiple monitoring systems.

In addition, many utilities are facing an aging workforce, which will be retiring in the next 5 to 10 years. Utilities need to fill their pipeline of talent with a younger workforce that is capable of operating today's electric grid, but who can also help build the smart grid of the future. Utilities can benefit from substation automation by more efficiently using their existing workforce and reducing the amount of service calls through programs such as condition-based maintenance.

Further, substation automation allows utilities to extract further value from their corporate networks by providing a remote workforce secure access to applications and data that are located in the operations center.

• Reduce capital expense: As demand for energy continues to grow, utilities must find ways to generate power to meet peak loads. As a regulated industry, utilities must provide power regardless of the amount of power consumed. The cost of providing spinning reserves for peak load hours of the year is extremely high for society. Utilities are challenged to find new ways to shave peak load to help reduce costs and manage supply and demand of energy more efficiently.

Substation automation can be the enabling technology for mass-scale peak load shaving and demand response, which will reduce the need to build as many power plants to meet peak demand.

Additionally, substation automation can reduce the expense and complexity of dedicated control wiring between devices found in many transmission and distribution substations today by converging to an Ethernet-based network. Logical network segmentation and reconfiguration of IED connectivity are much simpler to achieve. Point-to-point wiring not only is expensive, but also increases the difficulty of fault isolation detection.

• Enable distributed intelligence: As network intelligence expands beyond the control center out into the substations, new applications can be developed that enable distributed protection, control, and automation functions. A distributed intelligent network also introduces opportunities for new service creation, such as business and home energy management.

• Meet regulatory compliance: For many governments, utilities are considered critical infrastructure and have economic and national security concerns. Because of this, various regulatory mandates exist or are emerging that require utilities to secure, monitor, and manage their critical data networks in accordance with regulatory requirements, such as NERC-CIP.

• Improve grid security: Grid security is not just about securing the electronic security perimeter in the substation; it is also about creating a secure end-to-end architecture that maximizes visibility into the entire network environment, devices, and events.

Substation automation enables an important part of the end-to-end security architecture and allows network operators to control network users, device, and traffic. Physical security can be layered on top of this network security to create security zones of access control, IP cameras for surveillance monitoring, and video analytics to protect and alert network administrators of intruders.

A secure IP network for transmission of grid communications, physical security, and remote workforce management applications can be achieved through substation automation.

Solutions Approach

The solutions-based approach to substation automation begins with understanding different use cases and benefits around substation automation and ends with designing complete solutions to address these use cases. Some use cases that were evaluated include:

• Next-generation substation automation with and without GOOSE (Generic Object Oriented Substation Events) messaging

• Substation automation with phasor measurement units

• Substation physical security

• Substation remote workforce management

• Substation remote engineering access

• Substation precise timing distribution

• Network and security management

• Condition-based maintenance

• Distributed analytics

• IP telephony

• Networking solutions: Building on great tradition of networking excellence, we sell, install, design, configure and troubleshoot advanced rugged networking equipment and scalable architectures to enable reliable and secure two-way communication between substation SCADA equipment and the Energy Management System. These products are designed with substation in utilities environments in mind and offer zero-touch configuration methods.

• Security solutions: Defense in depth, as opposed to point solutions, is crucial for securing substation communications. We offers and install security solutions on the host, on the routers, and on the switching platforms and specialized security solutions such as firewall, VPN, authentication, and IPS solutions. Encryption security solutions on the host, routers, switches, and appliances provide an end-to-end infrastructure that enables and protects critical communication networks.

• Network management solutions: Simple and common management software for managing thousands of substation devices provides easy policy enforcement across substations. We also offers management and alarm reporting system software that can collect alarms from all the networking devices (including switches and routers), security devices (ASA and IPS modules on the ASA), and integration with third-party devices.

Global Cyber Security

{ Cisco. IBM. vmware Partners }

MJF Global Cyber Security and design supported by SPAWAR

2010-03-01T09:24:00.000-08:00

Regressive state

On 08/12/09 at the Clara Mass Hospital during a conference when ask about Alzheimer's by Tom Thode from the observer newspaper Mr. Joseph president of the Mary Joseph Foundation reply, Alzheimer's is a thief it first robs the individual or individuals of everything then kill them slowly. Alzheimer's put the individual or individuals in a regressive state in other word it takes the individuals from an adult to a child in a regressive state in speech and behavior in this state the individuals cannot do anything for themselves, the individuals have to depend completely on their caregivers to feed and clean them, while they may be also in pain and cannot say.

When ask, what causes Alzheimer's he stated no one fully know but we can see inside the brain of individuals and the damage Alzheimer's disease causes.

In several cases I observed about 81 percent develop dementia/Alzheimer's. Loneliness seem to play a big role in triggering the disease more rapidly than usual...Looking at three individuals Mr. Carl Thomas. Tracy Richard and Ann Thompson, in each case shortly after these individuals had left alone to live on their own dementia came on rapidly then after a short time full blown Alzheimer's. Could it be the love, closeness and comfort they had with their wife, husband and children before which may causes the disease to be suppress.

What is Alzheimer's?

Alzheimer's is a progressive, degenerative disorder that affects the brain, it damages the brain cells responsible for intellectual functioning in the brain, including memory, intelligence, judgment and speech ... Alzheimer's lead to the loss of mental and physical functions.

Today a rare and aggressive form of Alzheimer's can happens in some people in their 30's and 40's.

Individuals with Alzheimer's loose their ability to perform the basic tasks that are part of every day life and up requiring constant care and supervision.

Alzheimer's statistics

* Over 8 million people in the United States and well over 30 million world wide suffer from Alzheimer's.

*Every 22 second someone some where in the world gets Alzheimer's disease.

*The average course of the disease from the time it is diagnosed to death is about 4 to 7 years.

Remember anyone can get Alzheimer's, many individuals who get Alzheimer's disease in the third world countries do not have anyone to take care of them so many ends on the street and in homes for the insane and crazy individuals only to get mistreated by other people.

Alzheimer's cost

The national tab for caring for individuals with Alzheimer's disease is estimated at well over $100 billion annually, and by 2050 it will be over $ 450 billion annually.

Alzheimer's disease costs U.S. businesses more than $80 billion annually, stemming from lost productivity and absenteeism by primary caregivers, and insurance costs.

The annual cost of caring for one individual with Alzheimer's disease in America ranges from nearly $18,800 to more than $43,000 today depending on the stage of the disease.

Alzheimer's find out more

Individuals with early-stage Alzheimer's account for about half of all Americans afflicted with the disease.

Until recently, doctors assumed there wasn't much to be done once a person was diagnosed with Alzheimer's patients were sent home with kind words, drugs that had a mild impact on symptoms and perhaps some advice on how to deal with the inescapable changes in their brains and the inevitable changes in their lives.

Now for example, the studies in mice engineered to carry the human gene for Alzheimer's, one, published in the Journal of Neuroscience, showed that the simple act of learning could have a profound impact on the buildup of the distorted proteins that cause memory loss in both humans and mice afflicted with the disease, Scientists form that mouse that had periodically been forced to learn to navigate a maze ended with fewer plaques and tangles of protein than intellectually idle ones.

So far, there's no proof that mental exercises can stave off Alzheimer's, but growing evidence suggests that it might be possible to slow down the disease impact. This doesn't necessarily mean that the mental activity prevents Alzheimer's. It's always possible that the people with the healthiest brains were able to stay more mentally active. Still Scientists say, the research does suggest that mental activity might help slows the symptoms.

Today Scientists are saying information stored in episodic memory is like the narrative of a short story. This kind of memory depends on the hippocampus, a part of the brain hit hardest by Alzheimer's. The brain regions involved in another kind of memory ... procedural memory... are less affected by the disease. Procedural memory is what allows us to learn a difference subject or language.

Alzheimer's. As the disease progresses, it robs the individuals of their memories and changes how they both think and behave. It's ultimately fatal.

Experts in the field of dementia/Alzheimer's had a meeting in Washington, DC 09/16/07 on dementia/Alzheimer's disease and its coming destructive progressive behavior to so many worldwide...It is very critical for Scientists Dr. Thomas Hall stated from W.H.O to find a cure or maintain it. More than 30 million people today have this brain wasting disease and this number will quadruple, to over 130 million by 2050. By 2050 1 in 78 persons worldwide especially those in the third world countries who will see a rapid increase in Alzheimer's disease. The problem today in most cases is Alzheimer's disease is very difficult to detect until it has progressed from mild memory loss to clear impairment. Patients eventually lose all ability to care for themselves.

Who may get Alzheimer's

Experts now said those who most often are anxious or depressed were 40 to 50 times more likely to develop mild cognitive impairment, a form of memory loss that is often a transitional stage between normal aging and dementia. Not only are these individuals losing cognition, but they are showing many of the changes in the brain that associated with Alzheimer's disease.

In early studies, some Scientists found people who are more prone to distress are more likely to develop Alzheimer's disease than their more carefree counterparts.

People with mild cognitive impairment have some trouble remembering things, but they do not have significant disability.Not all people with this problem develops Alzheimer's disease, a much more serious impairment, about 20 percent do, according to several scientific reports.

Questions ask by most people

How can we tell if memory loss is caused by Alzheimer's disease?
Are there any symptoms I should watch for and report?
What should I expect if it is Alzheimer's disease?
When should I come back for another visit?
Where can I go for more information?
If the memory loss is caused by Alzheimer's disease, which treatment is most appropriate?

Here are some of the symptoms

Short-term memory loss, like repeating the same question several times.
Trouble remembering easy words, like saying "that thing I write with" instead of "pen or pencil ."
Not wanting to do things you usually enjoy doing such as cooking.
Making bad judgments, like turning the heat up too high, leaving the stove, walking out into the pouring rain without an umbrella, forgetting where you put your keys, to eat, or giving lots of money to a stranger for no reason, getting lost.
Extreme personality changes, mood swings and getting upset easily.
Confusing things and people from the past with things and people from the present.

The latest test, and research suggests that chronic stress may harm parts of the brain responsible for responding to stress ... an area that is also associated with memory.

Studies have shown that while these medications such as Namenda and Aricept don't stop or slow down the disease, they can tune up the brain but they cannot stop Alzheimer's disease. There are no cure for Alzheimer's disease today on the market any where in the world.

We at the Mary Joseph Foundation are working with several organizations and doing everything possible to help find a cure for this deadly disease while at the same time we are helping patients who have Alzheimer's disease by giving them rooming, loving care, foods, vitamins, Memory Companion and removing them from the street who are homeless and from mental disturb homes and care for them. Our services are FREE.

Our mission

The Mary Joseph Foundation is interested in building relationships with more companies here in America to help increase awareness of dementia/Alzheimer's disease, our organization generates funds to further our mission.

We are eager to work with you and your company to explore how the Mary Joseph Foundation can best support your business goals and objectives. There are several ways we can work together include cause-marketing programs, product royalty promotions, ads and special events here in America and abroad.

Our mission is to eliminate dementia/Alzheimer's disease and to provide the best care and support to those living with Alzheimer's disease here in America and around the world.

Mary Joseph Foundation a non-profit international organization.
Register with the Federal government and incorporated in the state of New Jersey.

2010-01-04T07:14:00.000-08:00

Progressive memory loss.

This is the hallmark of Alzheimer's disease. Initially, only short-term memory is impaired, and the person merely seems forgetful. But because short-term memory is essential for absorbing new information, the impairment soon interferes with the ability to interact socially and perform one's work. Long-term memory may be retained longer, often in great detail, but it becomes fragmented as the disease progresses. Toward the final stage, people with Alzheimer's may be unable to recall their own names.

The cerebral cortex

The third level of the brain is the cerebral cortex, commonly called the "gray matter." The cerebral hemispheres contain two specialized regions, one dedicated to voluntary movement and one to processing sensory information. But most of the gray matter is the association cortex, which becomes progressively larger as animals move up the evolutionary ladder. The association cortex is the region of conscious thought: It is where you store memory and language skills, process information, and carry out creative thinking.

Inside the brain

In Alzheimer's disease, brain cells die and neuronal connections wither in all parts of the brain, but especially in the hippocampus and the amygdala — important parts of the limbic system that coordinate memory storage and recall — and the cerebral cortex, the seat of higher-level thinking, memory, and language.

A micro view of the brain

Up close, the brain is a web of interconnecting cells called neurons. How these cells communicate and what happens when these cells die form the basis of our understanding of brain disease.

How brain cells communicate

The neuron is the brain's basic unit for processing information. The human brain contains an incredible number of neurons — about 100 billion, give or take 10 billion. The neuron is a unique cell in activity and appearance. It generates both electrical and chemical signals, making it able to communicate quickly with distant neurons. Instead of the compact shape typical of other cells in the body, the neuron is like an oak tree with giant branches stretched out. Each neuron has a body containing a nucleus, one long fiber called an axon, and many shorter branching fibers called dendrites.

The neuron is both a receiver and a transmitter. When a neuron receives a signal, it generates an electrical impulse. This impulse travels through the neuron and down the axon to its end (the axon terminal). The signal is then passed on to other neurons. Viewed under a microscope, neurons look like a dense forest of trees whose branches are so closely intertwined that they appear to touch. But when the details are highlighted with a silver stain, it is clear that each cell is separated from its neighbors by tiny gaps called synapses. Because the electrical signal cannot bridge this space, some other mechanism is required for a neuron to communicate with its neighbors. This is where the neuron's chemical signal comes in.

Stored in the axon terminal are chemical messengers called neurotransmitters. The electrical impulse opens tiny pores in the axon terminal, allowing a supply of neurotransmitters to flood into the synapse. The chemical then attaches to receptors on a neighboring neuron. What happens next depends on whether the neurotransmitter has an exciting or inhibiting effect on the neuron.

How nerve cells communicate

Electrical signal travels down axon of neuron.
Chemical neurotransmitter is released.
Neurotransmitter binds to receptor site.
Signal continues into new neuron.
Reuptake occurs; neurotransmitter is transported back into the cell that released it.

An excitatory neurotransmitter passes the message on by creating an electrical impulse in the cell that receives it, and the process of electrical-to-chemical signaling is repeated. But if an impulse were to be transmitted to every neuron in the brain, the result would be chaos; much like a power surge can cause a short circuit, neurons firing all at once would cause a prolonged epileptic seizure. To safeguard against this happening, inhibitory neurotransmitters suppress communication to neighboring neurons.

Of the more than 20 chemical messengers discovered thus far, a few are fairly well understood. Several of them are involved in memory, including acetylcholine, serotonin, and dopamine. Many of these neurotransmitters have additional functions; for example, serotonin helps regulate sleep and sensory perception, while dopamine helps regulate movement.

As biological processes go, the speed of thought is rapid (although slow compared with a computer). Electrical impulses in some neurons reach speeds of nearly 200 mph, and transmission from cell to cell takes about a thousandth of a second. In addition, one nerve cell may have more than 1,000 synapses and, with a single impulse, can transmit simultaneously to all its neighbors.

Plaques and tangles

The brains of Alzheimer's patients contain neurofibrillary tangles inside neurons and clumps of fibers called neuritic plaques outside of neurons. A set of enzymes, called secretases, in the neurons cause plaques to form. The secretases snip pieces from a large amyloid precursor protein (APP), leaving behind fragments of amyloid proteins that snarl and clump with the debris of dying neurons (pieces of dendrites). In contrast to the neuritic plaques, neurofibrillary tangles form within neurons and are composed of aggregates of a different protein known as tau.

Beta-amyloid is a peptide composed of approximately 40 amino acids. Research has shed light on the chemical process responsible for the formation and deposit of this sticky, starchlike protein in the brains of Alzheimer's patients. This understanding has prompted pharmaceutical companies to start manufacturing drugs to block the formation of amyloid deposits (see "Amyloid production blockers").

These tangles and plaques, first described by Alois Alzheimer in 1907, have been the main focus of research for decades, and for good reason: The worse the mental deterioration, the more amyloid and tangles are found in brain tissue. The prevailing view among neurologists used to be that these deposits caused the mental changes in Alzheimer's disease.

However, tangles and plaques are not unique to this condition. Some are found in other dementing disorders, and a few are scattered about in the brains of healthy middle-aged and elderly people. Some neuroscientists have wondered if these occasional deposits might explain the mild forgetfulness associated with normal aging, but studies have cast doubt on this theory.

Studies now indicate that dementia in Alzheimer's patients is caused by the shrinkage and death of neurons and synaptic loss, not by tangles and plaques themselves. However, according to the leading hypothesis, amyloid deposits play an early role by setting in motion a cascade of biochemical events that causes the cells to shrink and die.

With advances in technology enabling them to count neurons, neuroscientists were able to make this discovery by examining brain tissue from 10 people with normal brain function who died after age 60. All the samples contained about the same number of neurons in an area of the association cortex richly supplied with nerves from the sensory region. For the first time, scientists had a standard for defining how many neurons were "normal" in the human brain. Furthermore, this finding indicated that neuron loss was not a product of normal aging.

Next, the researchers compared the normal samples with brain tissue from 10 people with Alzheimer's and discovered, on average, a 41% reduction in the number of neurons. And the longer dementia had been present, the fewer neurons were found. There was also a correlation with neurofibrillary tangles: People with the greatest neuron loss had more tangles, about 95% of which were inside the remaining neurons. However, loss of neurons was dramatically greater than the number of tangles.

The researchers offered "housekeeping" as a possible explanation for this discrepancy: Molecules that clear away dead cells in the body eventually removed the tangles. When they counted neuritic plaques, the researchers found no relationship with either neuron loss or disease duration, reinforcing the view that neuronal dysfunction and death cause dementia. Although tangles and plaques are still considered the diagnostic hallmarks of Alzheimer's disease, synaptic loss and neuron death correlate best with dementia.

Experts also believe that decreased levels of the neurotransmitter acetylcholine, a chemical that bridges synapses between neurons that affect memory, also contribute to the memory loss of Alzheimer's disease. In the cortex and hippocampus, where this neurotransmitter is needed for memory and learning, the acetylcholine-producing neurons (called cholinergic neurons) are normally plentiful. But of the several types of neurons that can degenerate in Alzheimer's disease, the cholinergic neurons are especially hard hit. As acetylcholine production falls in the cortex and hippocampus, dementia becomes progressively worse. By the time someone with Alzheimer's disease dies, the cortex may have lost 90% of its acetylcholine.

Other neurotransmitter abnormalities may also be present. Reduced levels of serotonin and noradrenaline have been found in some people with Alzheimer's disease. Imbalances among these and other neurotransmitters could explain why some patients experience sensory disturbances, depression, sleep problems, aggressive behavior, and mood swings.

Mary Joseph Foundation

137 1/2 Washington Ave, Suite 292

Belleville, New Jersey 07109
202-241-2880

2009-10-26T06:13:00.001-07:00

Sandra Day O'Connor makes plea for Alzheimer's FUNDING!

WASHINGTON... Speaking out for the first time about her husband's Alzheimer's disease, retired Justice Sandra Day O'Connor told senators Wednesday that the disease takes a "staggering toll" on families and said, "our nation is certainly ready, and have to get deadly serious about this deadly disease."
As she referred to her "beloved husband," John, and how he is "not in very good shape," her voice cracked.

Who feel it knows it...Living with this disease has been sad and difficult for my entire family or any family," O'Connor wrote in the testimony she prepared for Wednesday's morning session. "The disease begins quietly, with memory difficulties that gradually become more serious and much more frightening with each passing year. Then, what follows is confusion ... impaired judgment ... trouble expressing even the simplest thoughts .... disorientation ... and socially inappropriate behavior." Yet Sandra Day O'Connor who was the first woman on the Supreme Court, clearly conveyed her main message to the Special Committee on Aging: that Alzheimer's disease research must be expanded to find a CURE, and it will take both public and private funding, I must say every dollar count.

Speaking from experiences In Sandra Day O'Connor's actual remarks to the committee, she did not read that text and instead highlighted the need for policymakers to focus on research of this deadly disease that currently has no cure.

Senate Special Committee Hearing on Alzheimer’s

Sandra Day O’Connor and Newt Gingrich testify
The Senate Special Committee on Aging held a hearing to examine the tremendous burden Alzheimer’s poses not only to the estimated some 8 million Americans with the disease and their 12 million caregivers, but also to the healthcare system.

Recently, researchers identified abnormal tau protein in the entorhinal cortex before dementia was even clinically detectable. For years now most researchers targeted a different symptom, the amyloid beta plaques that gum up the spaces between the brain's neurons, causing them to die. You can now see many famous people such as Charlton Heston 1924-2008,former President Ronald Reagan and more who die from Alzheimer's disease on our web site ( my forum )

We are asking everyone for their support let us fight this disease together, I watch my mother and two of my cousins slowly past away from Alzheimer's disease.

Mary Joseph Foundation

We are trying our best to find a cure and at the same time helping individuals who have Alzheimer's disease.
There are still no CURE of any kind for Alzheimer's disease today on the world market... Dr.William Thomas.
Mary Joseph Foundation a non-profit international organization for Alzheimer's disease
Register with the Federal government and incorporated in the state of New Jersey.

2009-10-14T07:23:00.000-07:00

The loving letter to all Americans that make me cry.

Letter from President Ronald Reagan to the American people:
Nov. 5, 1994

My Fellow Americans,

I have recently been told that I am one of the millions of Americans who will be afflicted with Alzheimer’s disease.

Upon learning this news, Nancy and I had to decide whether as private citizens we would keep this a private matter or whether we would make this news known in a public way.

In the past, Nancy suffered from breast cancer and I had my cancer surgeries. We found through our open disclosures we were able to raise public awareness. We were happy that as a result, many more people underwent testing.

They were treated in early stages and able to return to normal, healthy lives. So, now we feel it is important to share it with you. In opening our hearts, we hope this might promote greater awareness of this condition. Perhaps it will encourage a clearer understanding of the individuals and families who are affected by it.

At the moment I feel just fine. I intend to live the remainder of the years God gives me on this earth doing the things I have always done. I will continue to share life’s journey with my beloved Nancy and my family. I plan to enjoy the great outdoors and stay in touch with my friends and supporters.

Unfortunately, as Alzheimer’s disease progresses, the family often bears a heavy burden. I only wish there was some way I could spare Nancy from this painful experience. When the time comes I am confident that with your help she will face it with faith and courage.

In closing, let me thank you, the American people, for giving me the great honour of allowing me to serve as your President. When the Lord calls me home, whenever that may be, I will leave with the greatest love for this country of ours and eternal optimism for its future.

I now begin the journey that will lead me into the sunset of my life. I know that for America there will always be a bright dawn ahead.

Thank you, my friends. May God always bless you.

Sincerely,

Ronald Reagan

I will always LOVE you.

"My fellow Americans, I have recently been told that I am one of the millions of Americans who will be afflicted with Alzheimer's disease."

When President Ronald announced that a decade ago, it shook us. Sure, everyone dies; and not all of us leave behind the legacy of winning the Cold War. But a disease that slowly robs you of your mental faculties is a nasty way to go.

Alzheimer's was the eight-leading cause of death in the U.S. in 2001 An estimated 5 million Americans and between 13 to 16 million people worldwide already suffer from the disease, and as populations age it's predicted that by 2020 more than 61 million people worldwide will be afflicted with this painful and deadly disease. Today in America there are more than 8 million people and growing who suffer from dementia/Alzheimer's. The Mary Joseph Foundation is working hard with several research organizations to see if we can find a CURE...In the mean time we will continue to take care of individuals who have dementia/Alzheimer's.

www.maryjosephfoundation.blogspot.com

www.marycharityfoundation.blogspot.com
http://www.ammado.com/nonprofit/maryjosephfoundation/articles/all

Mary Joseph Foundation a non-profit organization for Alzheimer's disease.
137 1/2 Washington Ave, Suite 292
Belleville, NJ 07109
Register with with Federal government and incorporated in the state of New Jersey.

2009-10-06T11:43:00.000-07:00

Alzheimer's, the cost and the pain

The elderly and anyone who suffer from dementia/Alzheimer's aren't able to say when something hurts or is sore, I know first hand because I experienced it with my own mother after seeing her painful suffering for eight years going from a strong healthy lady to a state of a little child then finally pasting in 1998 from this deadly and painful disease call Alzheimer's Frank Joseph president for the Mary Joseph Foundation stated while he was working for Chase Manhattan Bank he got the news in his office, it really hurt me to know someone who was so loving and kind had to suffer with so much pain. People with Alzheimer's may demonstrate their pain through behaviors like rocking or striking out, and we often dismiss these actions as symptoms of the dementia instead of pain, which is usually from a different problem. Arthritis, diabetic neuropathy, fractures, muscular contractures, bruises, abdominal pain and mouth ulcers are among the list of common ailments that go undetected. It is important for those who live or work with persons with dementia to know how to identify when an elderly person is experiencing pain - and receive treatment sooner rather than later.

It is very difficult to determine the depth of pain experienced by someone with dementia.

The long, painful and slow goodbye

Alzheimer’s disease was first diagnosed just over 100 years ago, yet it remains an area of high unmet medical need with a heavy burden of care. So where are research taking companies today?

Whoever and wherever the patient, Alzheimer’s disease can leave a trail of worn out, broken-hearted relatives as they care for their loved ones on a journey that cannot be reversed

Symptoms of Alzheimer’s include memory loss, confusion, impaired judgment, personality changes, disorientation and loss of language skills. It is the most common of irreversible dementia

In the absence of better therapy, this global health problem will only get worse as population age. Today in 2009 it is estimated there will be over 61 million patients with dementia by 2020.

Understanding the needs of people with Alzheimer’s

Our main gold is to eliminate Alzheimer’s disease through the advancement of research; at the same time to provide and enhance care and support for all affected by this disease, and to reduce the risk of dementia through the promotion of brain health. We are working very hard so that one day there would be a world without Alzheimer’s disease, but for now your donation allows us to build homes, give medicines, food, vitamins, care and also remove individuals who have Alzheimer’s disease from the street who are homeless and are from mental homes and care for them, our services are FREE.

In the case of Alzheimer’s, however, there is an additional need. “ Alzheimer’s is a condition that affects not only the patient but also the career, the patients family and society as a whole.”

While the core symptoms are memory and cognition loss, these can lead to other symptoms and physical ailments. “If an Alzheimer’s patient has trouble remembering the names of close friends and answering questions in social situations, chances are that this will eventually result in embarrassing social situations. In turn, this will lead to a lack of confidence and withdrawal.” says Dr. Jason Thode from the world health organization on Alzheimer's disease.

Alzheimer’s Facts

New study today shows over 30 million people worldwide now are estimated to have Alzheimer’s
More than 50 percent of people with Alzheimer’s live in developing countries. By 2050, this will be over 74 per cent.
Alzheimer’s can occurs at any age, even as young as thirty (30) years in some cases.
The new numbers shows total worldwide cost of dementia care is estimated to be well over US $460.5 billion annually
It is not possible to predict who will get Alzheimer’s- it can strike anyone irrespective of gender, caste, creed, culture or socioeconomic status
21 September marks Alzheimer’s Disease Day, an umbrella body for Alzheimer’s group around the world.

Brain changes precede memory loss:

In some cases the disease is very difficult to detect until it has progressed from mild memory loss to clear impairment, individuals eventually loose all ability to care for themselves and others.

The brain structure changes can be seen in clinically normal individuals, an average of two years before they are diagnosed with mild cognitive impairment. In Dementia/Alzheimer’s disease cases, lesions known as (plagues and tangles) from in the brain, due to the abnormal clumping of two proteins called beta-amyloid and tau. MRI showed loss of gray matter two to three years before symptoms.

In normal older individuals, MRI of the brain reveals loss of gray matter about two to three years before symptoms of the mind cognitive impairment set in.

Dr. William Thomas said.

It hurts me very, very much that tears sometimes come to my eyes to see so much people here in America and around the world suffers from Alzheimer’s disease and the children who go without food and many times are homeless.

Mary Joseph Foundation cares and we are doing everything possible to eliminate Alzheimer’s disease, homelessness and hunger.

Mary Joseph Foundation a non-profit international organization.

www.maryjosephfoundation.blogspot.com

www.marycharityfoundation.blogspot.com
http://www.ammado.com/nonprofit/maryjosephfoundation/articles/all

2009-10-05T11:28:00.001-07:00

Parkinson’s Disease, Multiple Sclerosis and Alzheimer’s Disease

New research is showing that two medications used for other disorders can significantly help patients wish Parkinson’s disease, MS and Alzheimer’s and other inflammatory diseases.

Actos, traditionally used for diabetes has been shown to decrease the inflammation associated with neurological diseases with few side effects. It also doesn’t lower one’s glucose if one is not a diabetic. The decrease in inflammation is also not associated with the typical side effects associated with other anti-inflammatory like steroids.

Minocyclin, an antibiotic has been shown in recent studies to reduce inflammation in the brain and nervous system. Specifically has been shown to inhibit Astroglial cells, which are the immune cells found in the brain.

In my practice, I have seen excellent results with the use of these medications, especially when combined with various natural therapies that reduce inflammation and improve brain function. As suppose to other medications that are now available for these diseases, Actos and Minocyclin address the underline cause of these disorders: they reduce the primary inflammatory process in the brain. Once the inflammatory process is reduce through the use of these medications and detoxification of chemicals and heavy metals such as lead and mercury, I focus on improving brain function with various natural compounds, many of which are found in the brain. This is point where science and art meet because one has to not only know the science but one has to intuitively feel how these various natural compounds work in fellowship with our own biochemistry and cell function. Some of these natural compounds are novel and promising. They include a new compound Phosphatidylserine, attached to DHA, which is naturally found in the brain, Prevagen which has been shown to improve brain function, high potency Curcumin, IV and IM Glutathione, Lipostable and others.

Our patients see profound changes both in motor function and control and also in cognitive and overall brain function. Our approach to neurodegenerative diseases is a perfect example of how traditional medicine and holistic medicine must merge in order to offer patients the most effective treatments.

Publisher's abstract: New England Journal of Medicine.

Subjects from the "Framingham Study" were examined over an eight-year period. Baseline homocysteine levels measured eight years earlier were examined in relation to those individuals who developed dementia on follow-up. The study concluded that an increased homocysteine level is a strong, independent risk factor for the development of dementia and Alzheimer's disease. Occurrence of Alzheimer's nearly doubled in subjects with the highest level of homocysteine.

Healthy homocysteine levels can be maintained with a combination of Folate. B12 and B6. The body-ready (conenzymated) form of these vitamins may help overcome obstacles to metabolizing homocysteine.

COGNITIVE DISTURBANCES CORRESPOND WITH HIGH HOMOCYSTEINE²
Publisher's abstract: Journal of Geriatric Psychiatry and Neurology.
When 101 patients complaining of cognitive disturbances were investigated using brain imaging, laboratory assessment, electroencephalography and Mini Mental State Evaluation, the results correlated high homocysteine in 33% of the patients with subjective memory complaints, 45% of patients with Alzheimer's disease, and 62% of the patients with vascular dementia.

HOMOCYSTEINE AND COGNITIVE DECLINE IN HEALTHY ELDERY³
Publisher's abstract: Dement Geriatr Cogn Disord. Homocysteine appears to be an independent predictor of cognitive decline in healthy elderly and exerts a maximal effect on spatial copying skills.

BRAIN LESIONS AND SILENT STROKES RELATED TO HOMOCYSTEINE⁴Publisher's abstract: Ann Neurol. Cerebral MRI scans revealed that as many as 28% of healthy people 60-90 years of age (1077 study participants) had white matter lesions and evidence of small strokes - two predictive indicators of dementia and stroke. Outcomes of the MRI scans were strongly associated with homocysteine levels, and the relationship was continuous with no obvious threshold below which homocysteine levels were not associated with risk of disease.

Healthy homocysteine levels can be maintained with a combination of Folate, B12 and B6. The body-ready (conenzymated) form of these vitamins may help overcome obstacles to metabolizing homocysteine.

ELEVATED HOMOCYSTEINE PREDICTS BRAIN DEGENERATION⁵
Publisher's abstract: Arch Neurol. A three-year follow-up within the British OPTIMA project showed that patients with baseline homocysteine levels greater than 11.2 mmol/L showed a more rapid progression of atrophy of the medial temporal lobe (which includes hippocampus) over a three-year period.

IMPAIRED COGNITIVE ABILITIES MOST FREQUENT IN GROUP WITH HIGH HOMOCYSTEINE⁶
Homocysteine Metabolism, 3rd International Conference 1-5 July 2001. Abstract 191.
The risk of impaired cognitive function (a decline of three or more points of the Mini Mental State Evaluation score) was almost four-fold among the 25% of subjects with the highest homocysteine levels, compared to subjects with 25% of the lowest values in a three year follow-up to a community based study of the elderly Dutch.

LOW FOLATE EQUALS HIGHER RISK FOR DEMENTIA OR COGNITIVE IMPARIMENT⁷
Publisher's abstract: Dement Geriatr Cogn Disord.
The odds of developing vascular dementia, cognitive impairment or fatal stroke was 2.42 times higher for study participants with the lowest 25% of blood folate readings in a five-year follow-up study of 369 healthy subjects from the Canadian Study of Health and Aging.

HOMOCYSTEINE LEVELS AND CEREBROVASCULAR RISK FACTORS⁸
Publisher's abstract: Arch Neurol.
Higher homocysteine levels are an independent risk factor for moderate to severe formation of cerebral white matter in individuals with Alzheimer's Disease, and of leukoaraiosis of the deep white matter in particular.

Healthy homocysteine levels can be maintained with a combination of Folate, B12 and B6. The body-ready (conenzymated) form of these vitamins may help overcome obstacles to metabolizing homocysteine.

FOLATE DEFICIENCY AND HOMOCYSTEINE IMPAIR REPAIR OF NEURONS⁹
Publisher's abstract: J Neurosci. Folate deficiency and homocysteine impair DNA repair in neurons, which sensitizes them to oxidative damage.

VASCULAR DAMAGE INDUCED BY HOMOCYSTEINE A RISK FACTOR FOR ALZHEIMERS DISEASE¹⁰
Publisher's abstract: Nutr Rev. Homocysteine is considered an independent risk factor for vascular disease, and this finding is consistent with the emerging hypothesis that vascular disease is a contributing factor in the pathogenesis of Alzheimer's disease.

Notes

Additional studies are underway to further demonstrate whether folate intake or lowering homocysteine levels consistently has a direct, causal role in risk reduction for memory decline, dementia or Alzheimer’s disease.
This article is not intended to replace the advice or attention of your doctor or other health care professional. Do not stop taking medications or start taking any nutrition supplement without first speaking to a qualified health care professional who specialize in Alzheimer's care and disease.

www.maryjosephfoundation.blogspot.com

www.marycharityfoundation.blogspot.com
http://www.ammado.com/nonprofit/maryjosephfoundation/articles/all

Mary Joseph Foundation a non-profit organization for Alzheimer's disease.
137 1/2 Washington Ave, Suite 292
Belleville, NJ 07109

Experimental Drugs on Alzheimer's patients

2009-09-09T06:58:00.000-07:00

FDA "black box" not associated with changes in atypical antipsychotic prescribing rates

Non-drug therapy improves brain blood flow

Homocysteine may predict decline in Alzheimer's

Large scale, systematic reviews of published research show that the currently approved Alzheimer's drugs are effective in providing modest but noticeable improvements to people in the mild to moderate stage of the disease, and also found mixed results regarding safety in some of these products, according to new research reported today in Madrid at the 10th International Conference on Alzheimer's Disease and Related Disorders (ICAD), presented by the Alzheimer's Association.

Also among the "Late Submissions" presentations on the last day of ICAD 2006 were:

A review of atypical antipsychotic prescribing in Alzheimer's in a large managed care database found that an FDA "black box" warning was not associated with a substantial change in prescribing patterns for up to 10 months after the warning was issued.

In people 65 and older, a nondrug therapy for mild cognitive impairment (MCI) including occupational therapy and aerobic exercise improved blood flow in areas of the brain normally affected in Alzheimer's, and also improved memory test scores.

Homocysteine levels in the blood may predict the rate of cognitive decline in Alzheimer's.

"The diversity of research in this session is a wonderful indicator of the vigor of Alzheimer's research," said Ralph Nixon, MD, PhD, a member of the Alzheimer's Association's Medical & Scientific Advisory Council. "And we will continue to move the field forward as fast as we are given money to move it with. While the current drugs provide some noticeable benefits for a period of time, with the aging of the Baby Boomers, we desperately need better therapies that slow, stop and even prevent Alzheimer's disease."

Nixon is Professor of Psychiatry and Cell Biology at NYU School of Medicine, and Director of the Center for Dementia Research at NYU's Nathan Kline Institute.

Systematic Review of the Evidence for Cholinesterase Inhibitors for Alzheimer's

Since the introduction of the first cholinesterase inhibitor (ChEI) as treatment for Alzheimer's, many clinicians have used the approved cholinergic drugs - donepezil, galantamine and rivastigmine - as first line therapies for mild to moderate Alzheimer's. (Tacrine, the first FDA approved ChEI for Alzheimer's, is no longer recommended because of side effects.) Yet, a debate on whether ChEIs are effective continues. For example, in 2005, the National Institute for Health and Clinical Excellence (NICE), which is the independent treatment advisory agency of the United Kingdom's government-funded National Health Service, reviewed its previous recommendation that the ChEIs be used for mild to moderate Alzheimer's. The draft revision indicated that the ChEIs would no longer be recommended as they were not cost effective.

"Due to widespread protests from the public and the medical profession, NICE is reconsidering and will recommend the ChEIs for moderate Alzheimer's only," said Jacqueline Birks, MA, MSc, CStat, of the Cochrane Dementia and Cognitive Improvement Group, Division of Geratology, Department of Clinical Medicine, University of Oxford.

To help inform this debate, Birks conducted a systematic review for the Cochrane Library of all blinded, randomized trials in which treatment for five months or longer with a ChEI was compared with placebo or another ChEI. The main outcomes were cognitive function, global function assessed by a clinician, mood and behavior, activities of daily living and reports of adverse events. She sought to evaluate the efficacy, tolerability and cost effectiveness of the three drugs at the recommended optimal doses in people with Alzheimer's of any severity.

The review included 9,200 patients from 18 trials. The results showed that treatment for periods of six months and one year with donepezil, galantamine or rivastigmine produced modest improvements in cognitive function (on average 2.5 points of the 70 point ADAS-Cog scale), activities of daily living and behavior compared to placebo. The Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) is the most generally accepted scale for measuring cognitive function in Alzheimer's. In addition, clinicians rated overall performance more positively in ChEI treated patients than the placebo group. According to Birks, none of the treatment effects are large.

The review also found that more patients in ChEI treatment groups (29 percent) drop out of research studies because of side effects than those who received placebo (18 percent). There also was evidence of more adverse events in patients treated with a ChEI than with placebo. Nausea, vomiting and diarrhea, were significantly more frequent in the ChEI groups than in placebo. There was some evidence that the use of donepezil is neither more nor less expensive that placebo when assessing total health care costs.

"We conclude that the cholinesterase inhibitors, donepezil, galantamine and rivastigmine, are efficacious for mild to moderate Alzheimer's, and that they show similar treatment effects," Birks said. "There is some evidence that the results are similar for severe dementia. It would be inappropriate to base a decision regarding the availability of ChEIs on their cost effectiveness, for which there is no good evidence."

Cholinesterase Inhibitors and Risk of Death in Vascular Dementia

Some concerns have been raised about the safety of drugs for Alzheimer's and dementia. Galantamine has been associated with an unexpected increased risk for death in trials of patients with mild cognitive impairment (MCI) but not in Alzheimer's. Galantamine is not currently approved for treatment of MCI. Also, a study of donepezil in vascular dementia resulted in increased deaths among patients taking the drug compared with placebo. Though donepezil is not approved in North America and Europe for treating vascular dementia, it is commonly used for this purpose and is approved in several other countries, mainly in Asia.

In light of these concerns, Lon S. Schneider, MD, professor of psychiatry, neurology, and gerontology at the University of Southern California, Keck School of Medicine, and colleagues from the Cochrane Dementia and Cognitive Improvement Group systematically reviewed the available double-blind placebo- controlled trials of cholinesterase inhibitors (ChEls) and memantine, a drug that is approved in the U.S. and E.U. for treatment of moderate to severe Alzheimer's, and statistically analyzed the studies to assess the risk of death. They identified 42 published and unpublished trials of ChEIs and 12 memantine trials. Most were of 6 months duration, totaling more than 20,000 patients in ChEI trials and about 3,600 in memantine trials. Ten trials were not included because the sponsors declined to provide required data.

Overall, when all the cholinesterase inhibitor studies were analyzed together or when the memantine trials were analyzed, the researchers found no evidence for increased risk of death with these drugs. Looking more carefully, they also found no evidence for increased risks in patients with mild to moderate Alzheimer's, the level of illness for with the ChEIs drugs are approved.

Unexpectedly, the researchers found decreased risk of death for those taking donepezil in four trials in moderate to severe Alzheimer's. They found approximately a 50 percent decrease in risk - a drop from about five percent in the placebo group to 2.5 percent in the donepezil group.

"This effect implies a substantial potential public health impact," Schneider said, "in that, for every 41 patients with moderate to severe Alzheimer's treated with donepezil, statistically one death could be prevented over the course of about six months." Donepezil is not approved for treatment of severe Alzheimer's, and only recently have trials of cholinesterase inhibitors in severe Alzheimer's been done.

With respect to risks for donepezil in vascular dementia, the researchers found only three studies, which had great statistical variability among them - two showing increased risk and one showing decreased risk.

"This is concerning," Schneider said. "More studies are needed as a potential increased risk for death could be as high as three times that of people who are not treated. Our study shows why careful examination of all clinical trials together is required to better assess medications' efficacy and safety implications, and also why results from all clinical trials with drugs for Alzheimer's should be made public."

FDA Warning Not Associated with Substantial Decline in Use of Atypical Antipsychotics in Alzheimer's Population

In April 2005, the U.S. Food and Drug Administration (FDA) requested that drug manufacturers add a "black box" warning to prescribing information for atypical antipsychotic drugs because they were determined to be associated with increased mortality in elderly people with dementia with a rate of death estimated at 1.6 to 1.7 times greater than that of placebo. Most deaths were either heart-related or from infections.

Atypical antipsychotics are regularly prescribed to treat a group of very common and very debilitating symptoms often referred to as "behavioral and psychiatric symptoms of dementia," though they are not approved for that purpose. These symptoms include anxiety, depressed mood, hallucinations, delusions, aggression, agitation, wandering, culturally inappropriate behaviors, and sleep disturbances. According to the International Psychogeriatric Association, approximately 83 percent of patients with dementia demonstrate some type of behavioral disturbance.

According to the Alzheimer's Association, people with Alzheimer's and their families often report that these behavioral and psychiatric symptoms are more difficult to manage and cause greater distress than the more well known cognitive symptoms of memory loss, language problems, and reasoning impairment. Behavioral symptoms are often a determining factor in a family's decision to place a loved one in residential care. After placement, these symptoms can have an enormous impact on care and quality of life for individuals living in long-term care facilities.

To examine the number and types of prescriptions being used by clinicians to treat these symptoms in patients with dementia, Henry J. Riordan, Ph.D., of i3 Research, Basking Ridge, NJ, and colleagues examined prescribing trends of atypical antipsychotic agents in the elderly demented patient population by examining the claims database of a large U.S. health plan for a 10-month time period both before and after the FDA warnings were issued. Keeping patient identity anonymous, they included data for all those over 65 years of age with a diagnosis of dementia of any type, including Alzheimer's, who received a prescription for an atypical antipsychotic during this time period.

There were approximately 900,000 people aged 65 and over included in the database. The researchers found that of these, 4,715 had a diagnosis of dementia and were taking an atypical antipsychotic before the black-box warning was issued. Following the warning, 4,545 people with dementia had a prescription claim for an antipsychotic medication, a 3.6 percent decrease.

Data indicate that the FDA black-box warning was not associated with a substantial decrease in the use of atypical antipsychotics in this elderly population with dementia. One interpretation suggested by Riordan is that the benefits of these atypical antipsychotic agents are perceived by prescribers to outweigh their associated risks or the risks associated with no treatment at all.

Riordan further noted that, "As other therapies may not be considered as effective in treating these symptoms, or cause undesirable side effects, clinicians are left with few choices. This suggests an unmet need for new, safe and effective therapies for the behavioral and psychiatric symptoms in Alzheimer's."

Non-Drug Treatment (Exercise & Occupational Therapy) Improves Brain Blood Flow in MCI

A team led by Seigo Nakano, MD, PhD, at the Fifth Department of Internal Medicine, School of Medicine, Fukuoka University, Fukuoka, Japan evaluated the effects of a non-drug therapy on regional cerebral blood flow in amnestic MCI (MCI with memory loss only) among seniors living in the community.

"I was particularly motivated to examine nondrug therapy to prevent further increases in medical expenses as Japanese society is aging at an extremely rapid pace," Nakano said.

The scientists evaluated 32 amnestic MCI subjects aged 65 years or above in Ajimu, Japan. Eighteen participants received nonpharmacological interventions, and 14 control subjects did not. The intervention included occupational therapy, which was planning and doing simple tasks, and aerobic exercise of climbing up and down a step. Specifically, those in the intervention group helped with the renovation of an old building. During the course of the project, they did planning and were assigned to simple tasks. They also decided the menu for lunch, did shopping and cooked the meal. The seniors in the intervention group did these tasks once a week from November 2004 to November 2005.

All participants were given tests of memory, attention, verbal fluency, and other measures of mental functioning before and after the intervention; regional cerebral blood flow was measured using SPECT. On the baseline SPECT study, there was no significance between intervention and control groups. After one year of follow-up, the cognitive functions and regional cerebral blood flow were revaluated.

The researchers found that in the participants with MCI who received the therapy, the memory score and verbal fluency score after the therapy were significantly better compared to those who did not receive the therapy. According to the researchers, the cerebral blood flow of all participants before the intervention showed a pattern typically seen in early Alzheimer's; the blood flow in areas called the posterior cingulate gyri, precuneus and parietal lobules was low. One year later, the researchers observed that, in those who received the therapy, the overall area with low blood flow became smaller and the blood flow in areas usually low in Alzheimer's was improved.

"In people with amnestic MCI, our nondrug therapy may improve cerebral blood flow in areas that usually decrease in Alzheimer's," Nakano said. "This suggests possible effectiveness in preventing them from progressing to Alzheimer's, which deserves further study."

Homocysteine Levels May Predict Rate of Decline in Alzheimer's

In Alzheimer's, the decline in memory and other cognitive skills over time occurs at different rates in different people. For some, the decline is rapid so that in a few years they cannot cope with living on their own, no longer recognize friends or family and require full-time care. In others, the decline is slower and it may be 10 years or more before the final stage is reached. Little is known about why these rates of decline differ so much between individuals.

A team from the University of Oxford led by Professor David Smith, using statistical methods devised by Dr. Abderrahim Oulhaj, believes that the level of homocysteine in the blood may be one factor that predicts the rate of decline. Homocysteine is an amino acid that is involved in metabolism in cells of the body and which passes out into the blood. Elevated blood levels of homocysteine have been linked to increased risk of premature coronary artery disease, stroke, and venous blood clots, even among people with normal cholesterol levels.

In this new study, the researchers examined the association between the level of homocysteine measured when a person with Alzheimer's first visited the clinic and the subsequent rate of decline in cognitive skills. 102 people with a clinical diagnosis of Alzheimer's were evaluated every six months using CAMCOG (the cognitive and self-contained part of the Cambridge Examination for Mental Disorders of the Elderly) for a minimum of 18 months (three bi-annual visits) up to a maximum of 11 years. The CAMCOG is a brief neuropsychological battery designed to assess cognitive functions, and to detect mild degrees of cognitive impairment.

The scientists found that the higher the homocysteine level at the first measurement, the more rapid the subsequent decline.

"A model that best fitted the results was not a straight line but a curved rate of decline," Smith said. "The decline starts slowly, accelerates and then occurs rapidly, finally slowing again."

The researchers also observed a strong relationship between the concentration of homocysteine and the rate of decline; patients with twice as much homocysteine as other study participants declined twice as rapidly and reached the mid-point of their decline two years earlier. The relationship varied according to the age of the patient, and was strongest in patients younger than 75 at the start of the study.

"Because homocysteine can be lowered by taking high doses of folic acid and vitamin B12, the next step is to see whether B vitamin treatment will slow the rate of decline in Alzheimer's, giving people with the disease more time with higher levels of functioning," Smith said.

Mary Joseph Foundation a non-profit international organization.

Helping people who have Alzheimer's disease and children who are hungry especially in the third world countries, for more information call 202-241-2880.

Drugs Looks Promising for Alzheimer's disease

2009-08-18T07:33:00.000-07:00

More than 6 million Americans have Alzheimer's disease and well over 10 million baby boomers are expected to develop it in the coming years, which is why there's so much excitement about research being presented this week at a major conference of Alzheimer's experts.

New pill may restore memory loss in less than four weeks.
Dr. Marie Savard, boiled down some of the new developments that will be discussed at the conference.

Alzheimer's can be caused by the build-up of plaque in the brain and by fibrous tangles which wrap around nerve cells in the brain and kill the cells. Previous drugs have attacked the plaque, not very successfully.

A study was published recently that showed a drug called AL 108, which is actually a new type of nasal spray, attacks those fibrous tangles. Patients given AL 108 showed significant improvement in short-term memory after just four weeks and exhibited no side effects.

Testing of the drug is in early phase 2 trials, so a cure is not around the corner and there is no cure right now, but many researchers are excited about the findings.

Researchers at the conference will also present information about a powerful new test to detect Alzheimer's using PET scans.

PET scans have been very useful in detecting early-stage cancer, and researchers hope this new test could detect Alzheimer's as early as 10 years before people show symptoms of the disease, allowing them to begin treatment earlier.

The PET scan tests for Alzheimer's could be approved by the Food and Drug Administration in the next three or four years. PET scans are already widely used in hospitals to test for cancer and other diseases.

Antihistamine Looks Promising for Alzheimer's Patients
Alzheimer's disease can be heartbreaking to watch and frustrating to treat. Most medicines on the market do little more than delay the inevitable mental decline.

Preliminary tests show that Dimebon helps in restoring some memory.
But a new drug called Dimebon appears to stop and perhaps even reverse the symptoms of the cruel and degenerative disease, according to a new study published in the journal Lancet today.

"I was pleasantly surprised to see the effect on cognitive function, on memory, on activities of daily living that not only were clearly significant but seemed to increase over time," said Dr. Sam Gandy, former chairman of the Alzheimer's Association Medical and Scientific Advisory Council.

Dimebon wasn't designed to treat Alzheimer's disease. Far from it. It's an antihistamine that was supposed to treat allergies.

But a study that tracked 120 mild to moderate Alzheimer's patients for a year, and found that at six months those taking Dimebon three times a day showed significant improvement in mental tests and cognitive functioning, while those placed on the placebo kept deteriorating. A year into the study, the Dimebon group was still improving, while those without the drug were declining rapidly.

Hopes Dashed for Alzheimer's Drug
Researchers Abandon Flurizan; Doctors Hold Out Hope for Effective Approach
Many Alzheimer's researchers deny that the failure of a promising remedy for the degenerative disease requires a return to the drawing board, saying the setback is not a death knell for drugs designed to target a protein in the brain considered the trigger for the disease.

Still, doctors are disappointed that the treatment fell short of expectations -- especially when its makers spent $60 million on it during the past year alone.

On June 30, Myriad Genetics Inc. announced that its drug Flurizan didn't improve cognitive function or performance of daily activities for people who have Alzheimer's disease. A recent clinical trial tested the drug for 18 months in patients with a mild form of the condition.

"We are disappointed that Flurizan failed to achieve significance in this study, and we will now discontinue development of this compound," Myriad's CEO Peter Meldrum said in a statement.

Flurizan targeted one type of protein in the brain called beta amyloid. Researchers believe that the protein forms clumps that clog the connections between brain cells, which may contribute to the symptoms of Alzheimer's, which include progressive memory loss.

It was hoped that Flurizan would decrease the production of beta amyloid and slow the progression of the disease.

However, many scientists say they were not surprised by the findings. In fact, they say they even expected the outcome after seeing the underwhelming results of an earlier trial of the drug.

"The bottom line is that Flurizan was a nonstarter from the very beginning," says Rudy Tanzi, professor of neurology at Harvard Medical School in Boston. Tanzi is also the co-founder and shareholder of two companies that develop Alzheimer's treatments.

When results released in 2006 did not show an overall positive effect of Flurizan on brain function, Myriad researchers narrowed the patient population to target a small subgroup of people who benefited from the drug. They used this population -- patients who had mild Alzheimer's disease and took a high dose of the drug -- in the most recent trial.

But by that time, the earlier trial had already "cast considerable doubt on the potency of the drug in Alzheimer's disease," says Dr. Sid Gilman, director of the Michigan Alzheimer's Disease Research Center in Ann Arbor, Michigan...

"I have been skeptical of this all along," Gilman added.

Where to Go From Here
Doctors say that this latest defeat in the fight against Alzheimer's gives no indication of the state of research relating to the disease.

"Flurizan was the first shot on goal, but it was a shot from the 50-yard-line by a fifth grader," Tanzi says. "This is by no means a failure of all drugs that target amyloid beta."

Dr. Ronald Petersen, director of the Alzheimer's Disease Treatment Center at the Mayo Clinic in Rochester, Minn., agrees and says, "There are many other alternatives in the pipeline that show promise."

Among these are drugs aimed at various targets, Gilman says, including the immune system, receptors for various chemicals that bathe brain cells, and other pathways for stopping the pesky proteins that researchers believe contribute to Alzheimer's symptoms.

But treating and curing the condition may require a tag team of therapies to achieve the most effective results.

"I suspect that the reality is that attacking the amyloid cascade is a complicated issue, and no single therapeutic strategy is likely to be the final answer," Petersen says.

Scientists are optimistic that even with Flurizan's demise, a plausible treatment will emerge soon.

"History has shown that when you have a new mechanism and a new target, inevitably the first wave of drugs is usually the worst," Tanzi says, referring to the findings from Flurizan. "In these situations you need to be patient and wait for the second or third wave of drugs. ... That wave is coming."

There are still no CURE of any kind for Alzheimer's disease today on the world market... Dr.William Thomas.

Mary Joseph Foundation a non-profit organization for Alzheimer's disease.
137 1/2 Washington Ave, Suite 292
Belleville, NJ 07109
202-241-2880

Special project 81-49222-005A 2009

2009-08-18T07:14:00.000-07:00

We have come along way and I want to personally thank each and everyone of you for your support and tell you how important it is.With early onset of Alzheimer's detection and treatment the chance of slowing it down is much greater.As a special program of the Alzheimer's Foundation for detection of symptoms and prevention the mission of the Alzheimer's assistance relief fund is to support educational, prevention, medical assistance and relief, and innovative research programs in order to reduce the incidence of early onset of Alzheimer's disease in America and throughout the rest of the world.The Alzheimer's assistance relief fund is also fully committed to directly assisting patients, and caregivers with the personal devastation caused by Alzheimer's disease.

There are still no CURE of any kind for Alzheimer's disease today on the world market... Dr.William Thomas.

Thank you for your generous support, your gifts of $1.00 --$2.00 --$5.00 and $10.00, it provides and continue to provide another step closer to finding a CURE for Alzheimer's and at the same time helping those who have Alzheimer's disease, chance for life.

For every ten dollars $25 donation or more you make to the Alzheimer's assistance relief fund, you will get a gift from us that value upward of $20.000 in saving on food...We just want to say thank for your support.

Just by sending $1.00 or $2.00 it would be very, very much appreciated.With my humble and deepest gratitude,

Melrose Joseph,
Director for special needs

Please make check or money order payable to:
Mary Joseph Foundation for Alzheimer's disease
137 1/2 Washington Ave, Suite 292
Belleville, NJ 07109.
202-241-2880
http://www.ammado.com/badge.lnk/48246/La....png?w=150

Alois Alzheimer

2009-07-07T11:47:00.001-07:00

Alois Alzheimer was born in 1864 in Markbreit in Bavaria, Southern Germany. Excelling in sciences at school he studied medicine in Berlin, Aschaffenburg Tubingen and Wurzburg where he graduated with a medical degree in 1887. He began work in the state asylum in Frankfurt am Main, becoming interested in research on the cortex of the human brain. Here he commenced his education in psychiatry and neuropathology.

Along with Franz Nissl, a colleague at the asylum, Alzheimer spent the following years working on a major six volume study, the 'Histologic and Histopathologic Studies of the Cerebral Cortex,' describing the pathology of the nervous system. The work was finally published between 1907 and 1918. In 1895 Alzheimer was appointed director of the asylum where he continued his research on a number of subjects including manic depression and schizophrenia.

Today, the pathological diagnosis of Alzheimer's disease is still generally based on the same investigative methods used in 1906. This is remarkable compared with the development of investigative methods for other diseases, and it speaks volumes about the quality of Alzheimer's discovery.

Alzheimer's disease is the most common cause of dementia and accounts for 65% - 80% of all cases. It destroys brain cells and nerves disrupting the transmitters which carry messages in the brain, particularly those responsible for storing memories. Alzheimer's disease was first described by A. Alzheimer's in 1906.

During the course of Alzheimer's disease, nerve cells die in particular regions of the brain. The brain shrinks as gaps develop in the temporal lobe and hippocampus, which are responsible for storing and retrieving new information. This in turn affects people's ability to remember, speak, think and make decisions. The production of certain chemicals in the brain, such as acetylcholine is also affected. It is not known what causes nerve cells to die but there are characteristic appearances of the brain after death. In particular, 'tangles' and 'plaques' made from protein fragments are observed under the microscope in damaged areas of brain. This confirms the diagnosis of Alzheimer's disease.

Currently there are over 30 million peoples worldwide who are living with Alzheimer’s disease and that number is expected to grow to well over 61 million by 2020. Alzheimer’s disease is the seventh leading cause of death in the United States and number six worldwide.

Mary Joseph Foundation a non-profit international organization for Alzheimer's disease

137 1/2 Washington Ave, Suite 292

Belleville, New Jersey 07109

A world without Alzheimer's and hungry Children.

2008-12-10T09:12:00.000-08:00

We really cares about you!

Our main gold is to eliminate Alzheimer's disease through the advancement of research; at the same time to provide and enhance care and support for all affected by this disease; and to reduce the risk of dementia through the promotion of brain health. We are working very hard so that one day there would be a world without Alzheimer's disease, but for now with your donations its allow us to build homes, give medicines, foods, vitamins, caring and remove individuals who have Alzheimer's disease from the street who are homeless and from mental homes and cares for them, our services are FREE.

It hurt me very, very much that tears some times come to my eyes to see so much people here in America and around the world suffering from Alzheimer's disease and the children who go with out foods and many times are homeless.

Mary Joseph Foundation cares and we are doing everything possible to eliminate Alzheimer's disease, homelessness and hunger.

We are looking for more companies to work with us on Alzheimer's disease and children who are hungry and homeless.

To help please send all mails and donations to: Mary Joseph Foundation a non-profit organization, 137 1/2 Washington Ave, Suite 292, Belleville, NJ 07109

Melrose Joseph
Director
Mary Joseph Foundation

Every 22 seconds in the world and 71 seconds in America someone get Alzheimer's

2008-11-02T05:19:00.000-08:00

Autobiographical memory: Memory for the personal events and facts of one's life.

There is no single concept called " memory " There are two overarching types: short-term, which allows you to remember the beginning of this sentence by the time you reach the end of it, and long-term, which includes unconscious habits and reflexes, general facts and knowledge, and autobiographical memory ... memory for the personal details, facts and experiences of your life.

Just like the rest of our bodies, our brains change as we age. Most of us notice some slowed thinking and occasional problems remembering certain things. However, serious memory loss, confusion and other major changes in the way our minds work are not a normal part of aging.

Is a progressive and fatal brain disease. There are over 6 million Americans now have Alzheimer’s disease. Alzheimer's destroys brain cells, causing problems with memory, thinking and behavior severe enough to affect work, lifelong hobbies or social life. Alzheimer’s gets worse over time, and it is fatal. Today it is the seventh-leading cause of death in the United States.

We are doing everything possible to help individuals who have Alzheimer's disease and also to find a cure.

Changing The Present helps nonprofit's raise awareness Alzheimer's disease and raise money by making charitable giving more convenient, cost-efficient, and rewarding than ever before.

Register for a Premium membership for just a donation per year to take full advantage of our FREE services and online purchasing and fundraising.

Remember someone develops Alzheimer's disease
every 22 seconds and it could be you.

Don't let Alzheimer's steal
you or your love one dreams. Act now !!!

Mary Joseph Foundation a non-profit organization for Alzheimer's disease
137 1/2 Washington Ave, Suite 292
Belleville, NJ 07109
202-241-2880
www.maryjosephfoundation.org

To really see the suffering and pain that Alzheimer's disease causes you have to really see and experience the suffering of your dear love one, it was very, very hard for me to see my mother in so much pain, that many times tears would start coming from my eyes.

http://www.maryjosephfoundation.blogspot.com
http://www.marycharityfoundation.blogspot.com

All funds are going to help individuals who have Alzheimer's and hungry children.

2008-03-10T13:53:00.000-07:00

Alzheimer's disease and the affects.

2008-03-02T14:02:00.000-08:00

A few days ago several studies on Alzheimer's disease show

memories are first processed in the entorhinal cortex, which also is where Alzheimer's seems to begin its spread.

Evidence at the cellular level shows there are two causes for the onset of Alzheimer's. Starchy plaques crowd the space between brain cells. Tangles of tau proteins clomp together, sabotaging communication pathways.

For such important structure, little is known about the circuitry of the entorhinal cortex. What is known is that the activity levels of its neurons seem to predict whether something will be remembered or forgotten, for example the entorhinal cortex is the first area in the brain damaged by Alzheimer's. It is like a small fire set by an arsonist, the disease smolders here, then works upward through the centers of speech and language and spreads across the ceiling of the brain, moving into the visual cortex in the back, the motor cortex in the front, then into the most forward part, where cognition, judgment and reasoning reside.

Having dismantled the walls and floors of the brain's major lobes, Alzheimer's descends into the subcortex , finally attacking the brain stem and choking off the most basic processes of life, swallowing, breathing, blood pressure.

Recently, researchers identified abnormal tau protein in the entorhinal cortex before dementia was even clinically detectable. For years now most researchers targeted a different symptom, the amyloid beta plaques that gum up the spaces between the brain's neurons, causing them to die.

We are our memories, and almost everything we do is guided by the experiences we have had. All of our skills, our aspirations, our hopes, dreams, and imagination come out of our experiences and the accumulated benefit we have derived from them.

It is that very foundation, however, that turns tremulous for those with Alzheimer's.

All such memories are an amalgam of associations.

We are trying our best to find a cure and at the same time helping individuals who have Alzheimer's.

There are still no Cure on the market today for Alzheimer's disease...Dr. William Thomas

Mary Joseph Foundation
137 1/2 Washington Ave, Suite 292
Belleville, New Jersey 07109

More about Alzheimer's disease

2008-02-17T15:00:00.000-08:00

Until the late 1970s, the study of such personal memory was not considered suitable for scientific inquiry. Whatever played across the mind's screen was private and unknowable to the outside world.This lack of knowledge about how memory works made it almost impossible to unravel one of medicine's most vexing questions - the cause of Alzheimer's, an age-related disease affecting more than six million Americans.

But an examination of the latest research, some of it not yet published, shows that, neuron by neuron, scientists are finally making their way into the deepest recesses of human memory. Like the first blurry, black-and-white pictures sent back from the surface of the moon, the view is still imperfect, but memory's secret landscape is slowly being revealed.For example Scientific are now using laser and different type of wire devices to cause regression to the memory.

Science is unlocking many of the mysteries of the brain, but we don’t have all the answers yet. You can do everything “right” and still not prevent Alzheimer’s disease. What’s offered here is the best and most up-to-date information available so that you can make your own decisions about your health.

Mary Joseph Foundation

http://www.miltilinkwithpeoplesandcorpor...ogspot.com

http://www.maryjosephfoundation.blogspot.com

http://www.marycharityfoundation.blogspot.com

Anyone can get this deadly disease.

2007-10-15T06:44:00.000-07:00

Letter from President Ronald Reagan to the American people:
Nov. 5, 1994

My Fellow Americans,

I have recently been told that I am one of the millions of Americans who will be afflicted with Alzheimer’s disease.

Upon learning this news, Nancy and I had to decide whether as private citizens we would keep this a private matter or whether we would make this news known in a public way.

In the past, Nancy suffered from breast cancer and I had my cancer surgeries. We found through our open disclosures we were able to raise public awareness. We were happy that as a result, many more people underwent testing.

They were treated in early stages and able to return to normal, healthy lives. So, now we feel it is important to share it with you. In opening our hearts, we hope this might promote greater awareness of this condition. Perhaps it will encourage a clearer understanding of the individuals and families who are affected by it.

At the moment I feel just fine. I intend to live the remainder of the years God gives me on this earth doing the things I have always done. I will continue to share life’s journey with my beloved Nancy and my family. I plan to enjoy the great outdoors and stay in touch with my friends and supporters.

Unfortunately, as Alzheimer’s disease progresses, the family often bears a heavy burden. I only wish there was some way I could spare Nancy from this painful experience. When the time comes I am confident that with your help she will face it with faith and courage.

In closing, let me thank you, the American people, for giving me the great honour of allowing me to serve as your President. When the Lord calls me home, whenever that may be, I will leave with the greatest love for this country of ours and eternal optimism for its future.

I now begin the journey that will lead me into the sunset of my life. I know that for America there will always be a bright dawn ahead.

Thank you, my friends. May God always bless you.

Sincerely,

Ronald Reagan

Please support us in our non-profits work here and in many third world countries, especially in the third world countries it is real bad.

alzheimers@maryjosephfoundation.org

www.maryjosephfoundation.org

The deadly disease that affect us in so many ways.

2007-10-02T11:42:00.000-07:00

In honor of the late Mary Joseph who past from Alzheimer's disease in 1998.

Alzheimer’s disease was first diagnosed just over 100 years ago, yet it remains an area of high unmet medical need with a heavy burden of care. So where is research taking companies?

Whoever and wherever the patient, Alzheimer’s disease can leave a trail of worn out, broken-hearted relatives as they care for their loved one on a journey that cannot be reversed.

Alzheimer’s is a progressive, irreversible brain disorder with a poorly understood cause and no known cure. It attacks and slowly steals the minds of its victim and brings heartache to the career, often a relative, who must watch their loved one slip away to a loathsome thief.

Symptoms of Alzheimer’s include memory loss, confusion, impaired judgment, personality changes, disorientation and loss of language skills. It is the most common form of irreversible dementia.

In the absence of better therapy, this global health problem will only get worse as populations age. It is estimated there will be over 51 million patients with dementia by 2020.

Understanding the needs of people with Alzheimer’s

Myths and misconceptions about Alzheimer’s

The World Health Organization says Alzheimer’s disease has many myths and misconceptions.

For example, some people regard the disease as the same as ‘going mad’, and others ask about the need to go to a doctor if Alzheimer’s is ‘part of getting old’.

As a director in the Business and Commercial Analysis group of GSK's Research & Development division, one of Jaron Ballentine’s responsibilities is to help the company better understand the needs of patients and physicians so it can develop better medicines.

In the case of Alzheimer’s, however, there is an additional need. “Alzheimer’s is a condition that affects not only the patient but also the career, the patient’s family and society as a whole,” he says.

While the core symptoms are memory and cognition loss, these can lead to other symptoms and physical ailments. "If an Alzheimer’s patient has trouble remembering the names of close friends and answering questions in social situations, chances are that this will eventually result in embarrassing social situations. In turn, this will lead to a lack of confidence and withdrawal," says Jason.

Caring for the care-giver

Alzheimer’s concerns more than the patient, of course. Most have a career or care-giver who takes primary responsibility for their well-being. This person is usually a loved one – over 80 per cent of careers are a partner, spouse or relative, usually a son or daughter. A majority of careers are retired or homemakers; about 30 to 40 per cent have part-time or full-time jobs which place additional burdens on them. The time given to caring has been compared to having another job.

“Regardless of the circumstance, caring for an Alzheimer’s patient takes dedication and self-sacrifice. We are told that 70 per cent of care-givers have
reported they have decreased social activities as a result of being a care-giver. About half of them have limited hobbies or have given them up, and almost ten per cent have changed or given up their job.” This significant care-giver burden is a factor that is now measured in Alzheimer’s trials at GSK. “The hope is that the medicines we are developing for Alzheimer’s will not only benefit the patient but also improve the care-giver’s quality of life.”

Alzheimer’s is a condition that affects not only the patient but also the career, the patient’s family and society as a whole.

The emotional aspects of Alzheimer’s should not be forgotten. “Most careers are either a husband or wife, or a son or daughter, and they love the patient dearly. They recognize that while it is a significant sacrifice, they feel strongly that they want to take good care of their loved one and ensure they are well cared for and comfortable. It is the family who sees the patient slowly fade away, in what many call ‘the long goodbye’.”

Research directions for Alzheimer’s
So what are companies such as GSK doing to combat this soul-destroying disease?

Current mainstream therapies work by reducing the degradation of the neurotransmitter acetylcholine in the synapse (the region where nerve impulses are transmitted and received between nerve cells). If the level of acetylcholine in the synaptic areas of the brain can be maintained, memory dysfunction can be improved.

”Some of the therapies we are developing modulate and up-regulate the release of neurotransmitters. Other approaches endeavour to mimic the effect of the missing neurotransmitters or increase the response of the receiving cells to those transmitters,” says John Davis, director of one of the Molecular Discovery Research units in GSK's Research & Development division.

Avenue of exploration
The fact that energy metabolism appears to be affected in Alzheimer’s disease is offering GSK a further avenue of exploration. “Drugs that can modulate glucose utilization, like those currently used in diabetes, are a good bet in trying to modulate glucose utilization in the brain,” says John.

“By having a number of symptomatic approaches, we hope to produce new therapies for patients that have improved or different side-effect profiles. We also hope to produce improved efficacy - or at least efficacy that can be added to existing treatments - so that the armoury which physicians have to combat the disease is increased.”

However, the problem with symptomatic treatments is that they do not tackle the underlying progression of the disease. “If a patient’s drug is removed, we may find that their condition deteriorates rapidly in response, so we are also looking for disease-modifying therapies that will tackle the underlying cause of the disease.”

Going back to Alois Alzheimer

As well as having a number of symptomatic treatments in the clinical pipeline, GSK is looking at somehow modifying the disease.

Alzheimer’s facts

Over 30 million people today worldwide are estimated to have Alzheimer’s
More than 50 per cent of people with Alzheimer’s live in developing countries. By 2050, this will be over 74 per cent
Alzheimer’s can occur at any age, even as young as 30 years
The total worldwide cost of dementia care is estimated to be US $460.4 billion annually.
It is currently not possible to predict who will get Alzheimer’s - it can strike anyone irrespective of gender, caste, creed, culture or socioeconomic status
21 September marks Alzheimer’s Disease Day, organised by the Alzheimer’s Disease International, an umbrella body for Alzheimer’s groups around the world.

Here, researchers have returned to some of Alois Alzheimer’s original observations, one of which concerns characteristic plaques in the brain. These contain a substance called beta-amyloid, which is thought to be important in the progression of the disease.

GSK is investigating a number of disease modifying approaches that aim to lower amyloid levels in the brain.

Focus on the Alzheimer’s patient
"In the past few years we have been conducting some ground-breaking work using large patient populations to work out how patients can help in developing new therapies and approaches towards delivering drugs," says John.

"On the one hand we have conducted genetic association studies, where we can identify genetic mutations carried in the population that predispose those patients towards contracting or developing Alzheimer’s disease. The other way of using these large banks of data derived from patients is to look for biomarkers of the disease or physiological processes that can be targeted in the pathology of the disease." The hope is that these markers may then be used to manage the development of therapeutics more efficiently.

There are many people, among them the careers and those who are and will be patients, who are hoping the research paths being taken now - 100 years since Alois Alzheimer first described this saddening disease - are fruitful ones.

Mary Joseph Foundation a non-profit international organization

137 1/2 Washington Ave, Suite 292

Belleville, New Jersey 07109

Build and protect your memory.

2007-09-23T13:18:00.000-07:00

Memory Companion;

It is a fortify blend formula with all natural herbal plants and all the essentials elements for everyone memory. Memory Companion maintain and keep your memory functioning properly and in great healthy condition, the memory is very important it is the faculty by which the mind stores and remembers information, more than ever in today world your memory need help and Memory Companion is the one you should be taking.

Memory Companion help produce new cells for growth and other vital functions that helps improve your memory by preventing and removing plaques from building up, it promotes mental function and healthy cells.

Memory Companion formula has in over twenty difference type of herbal plants, these plants are the most concentrated source of omega-3, amino acids, antioxidants and more vital essentials for your memory and Brain from all these natural herbal plants.

To avoid damage cells and plaque build up that causes Dementia/Alzheimer's, you need Memory Companion.

To buy Memory Companion please send $35.00 for a 22 oz bottle plus $4.00 for shipping and handling to,

Mary Joseph Foundation

137 1/2 Washington Ave

Suite 292

Belleville, New Jersey 07109.

Memory Companion only cost $35.00 per 22 oz bottle plus $4.00 for shipping and handling, remember every 22 seconds someone in the world will get Alzheimer's disease, so please protect yourself.

We guarantee your satisfaction when you use this product. If you are not satisfied, just return the unused portions for a full purchase price refund within 90 days of purchase.

What is Alzheimer's.

2007-09-21T13:33:00.001-07:00

About Alzheimer'S disease;

Alzheimer's disease is a degenerative disease characterized by progressive deterioration with declining activities of daily living and symptoms or behavioral changes, it is the most common type of Dementia. Alzheimer's is a progressive BRAIN disorder that cause by PLAQUES and gradually destroying the individuals memory and ability to learn and reason, make judgments, properly communicate with others and carry out daily activities. As Alzheimer's progresses, individuals will also experience changes in their personality and behavior, such as anxiety, suspiciousness or agitation and delusions back and forth from adult to a child like state and finally remain in a child like state.

Dr. William Thomas

Mary Joseph Foundation

Job postings.

2007-09-18T10:30:00.001-07:00

We have two opening;

Director, for future planning here in America and abroad, meeting with government and Business leaders.

Communications and Fundraising Specialist, setting up auctions, meeting with business leaders.

Send resume to

Mary Joseph Foundation

137 1/2 Washington Ave, Suite 292

Belleville, New Jersey, 07109

Atten: Melrose Joseph

www.maryjosephfoundation.org

Caring.

2007-09-10T09:35:00.000-07:00

Yvonne,

There is a big problem today especially in many of these homes that are caring for your love ones with Alzheimer's,I see it first hand over and over, my mother was in the same condition so we had to take care of her ourselves, then traveling to many countries I saw many individuals who have Alzheimer's/Dementia living on the street homeless and some are put in homes for the insane, crazy and beaten sometimes by the guards. We at MARY JOSEPH FOUNDATION remove individuals who have Alzheimer's/Dementia from the street and homes for the insane, crazy and others bad places especially in the third world counties and take care of them like our own family. Yvonne it is ashame that these things happen to our love ones because we just want the best for our love ones, but in the mean time try talking to the head of the facility about feeding times and turning times for you love one.

Remember no one should ever go through this alone Alzheimer's disease, Alzheimer's disease bring you right down to nothing, it destroy you.

Thank you Yvonne for your email

Joan White, Director of care.

Mary Joseph Foundation feed, give vitamins, medicines, caring and rooming to individuals who have Alzheimer's/Dementia.
We continue to build homes and help individuals who have Alzheimer's disease.

We need volunteers.

2007-09-03T12:41:00.000-07:00

We are looking for volunteers in difference fields:

Management. Government. Building. Public relations. Patients care and others.

Today the world that we are living in, is such a small place and there are so, so much peoples who are suffering from so many difference types of disasters and diseases, here and around the world and these peoples need our help.

We at Mary Joseph Foundation cares for individuals who have Dementia/Alzheimer's disease by providing FREE foods, vitamins, medicines, caring and rooming for them.

We remove many Dementia/Alzheimer's individuals from the street and homes for the insane.

We at Mary Joseph Foundation hope to continue doing our best for individuals with Dementia/Alzheimer's here and in the third world countries.

Please send us your resume with your work experience to the Mary Joseph Foundation
137 1/2 Washington Ave, Suite 292, Belleville, New Jersey 07109

Dementia/Alzheimer's.

2007-09-01T12:14:00.001-07:00

Brain changes precede memory loss:

In some cases the disease is very difficult to detect until it has progressed from mild memory loss to clear impairment, individuals eventually loss all ability to care for themselves.

The Brain structure changes can be seen in clinically normal individuals an average of two years before they are diagnosed with mild cognitive impairment.

In Dementia/Alzheimer's disease cases, lesions known as ( plaques and tangles ) form in the brain, due to the abnormal clumping of two proteins called beta-amyloid and tau.

MRI showed loss of gray matter two to three years before symptoms.

In normal older individuals, MRI of the brain reveals loss of gray matter about two to three years before symptoms of the mind cognitive impairment set in.

Dr. William Thomas

Protect your memory and avoid Dementia.

2007-08-28T17:02:00.000-07:00

Build a strong memory:

Memory Companion is fortify with over twenty difference types of all natural herbal plants, in 2003 we tested Memory Companion on over one thousand individuals who had plaque problem with their memory and after six months of taking Memory Companion the plaque build up was removed and new cells reappear in the individuals brain.

We also realize when an individual take Memory Companion at a real early stage in life their memory tend to be plaque FREE.

Plaque is a sticky build up that form and deposit on certain parts of the brain which causes individuals to become forgetful and later Dementia/Alzheimer's.

Dr. William Thomas

www.maryjosephfoundation.org

Protect your Memory.

2007-08-22T10:44:00.000-07:00

George thank for your question?

Yes there are very good formulas out there to avoid Dementia, one of the best I know of and use myself is Memory Companion, and also use by thousands of peoples to help repair damage cells from dying off by removing the plaques and stop plaques from sticking to the cells and at the same time help boost your memory and protect it.

Joan thank for your question?

The memory is the faculty by which the mind stores and remembers information, and also the length of time over which people's memory extends, as we grow older we need to take care of our memory we think Memory Companion is one of the best product for the memory.

for more information on Memory Companion please send us an Email:

alzheimers@maryjosephfoundation.org

A few questions and answers.

2007-08-21T13:20:00.000-07:00

Thank Marjorie for your question?

Individuals who have Dementia goes through these changes because it is
A mental disorder marked by memory failures, personality changes, and
impaired reasoning.

Never argue back with him instead always invite him to do something else
and while he is doing something else you remove his pack baggage and
because of memory failure, when he return he will forget that he was
leaving.

Thank Shirley for your question?

You should always turn your mother every two hours in Bed to avoid damage
to her skin.

Please help us to help those in need.

2007-08-21T12:54:00.000-07:00

www.marycharityfoundation.blogspot.com

Please join us in helping to find a cure and continue feeding, giving medicines, vitamins and rooming to individuals who have Alzheimer's/Dementia. We provide these services for FREE because of your donations.

Mary Joseph Foundation
Suite 292
137 1/2 Washington Ave
Belleville, NJ 07109

alzheimers@maryjosephfoundation.org

Signs and symptoms of Alzheimer's.

2007-08-19T15:41:00.000-07:00

Question ask by most peoples?

How can we tell if memory loss is caused by Alzheimer's disease?
Are there any symptoms I should watch for and report?
What should I expect if it is Alzheimer's disease?
When should I come back for another visit?
Where can I go for more information?
If the memory loss is caused by Alzheimer's disease, which treatment is most appropriate?

Here are some of the symptoms:

Short-term memory loss, like repeating the same question several times.
Trouble remembering easy words, like saying "that thing I write with" instead of "pen or pencil ."
Not wanting to do things you usually enjoy doing such as cooking.
Making bad judgments, like turning the heat up too high, leaving the stove, walking out into the pouring rain without an umbrella, forgetting where you put your keys, to eat, or giving lots of money to a stranger for no reason, getting lost.
Extreme personality changes, mood swings and getting upset easily.
Confusing things and people from the past with things and people from the present.

there is no cure for Alzheimer's:

You can keep yourself healthy by taking vitamins, omega-3 fatty acids and others, to learn more email us at alzheimers@maryjosephfoundation.org

There are some medications can help slow Alzheimer's down, but first check with your Doctor.

Mary Joseph Foundation

Suite 292

137 1/2 Washington Ave

Belleville, NJ 07109

Looking at Dementia/Alzheimer's:

Dementia!

A mental disorder marked by memory failures, personality changes, and impaired reasoning.

Alzheimer's!

A form of progressive mental deterioration occurring in middle or old age and in some rare cases individuals in their thirties.

These causes individuals to become forgetful and confused and slowly robbing them of their memory, it happen when the brain cells die and a sticky plaques form and cover over certain parts of the brain.

Do you have a question send us an email: alzheimers@maryjosephfoundation.org

Some of our services.

2007-08-18T21:34:00.000-07:00

Mary Joseph Foundation services:

We provide Rooming, foods, medicines and vitamins for individuals who have Alzheimer's disease, many were homeless or in homes for the mental disturb.

We are now working with a Pharmaceutical company on some experimental medicines for individuals who have Dementia and Alzheimer's disease.

*Every 22 second someone some where in the world get Alzheimer's disease''

We are also fighting hunger around the world because we believe no one should be or go hungry. It is a shame every minute of every day, somewhere in the world, between 25 to 28 children die of malnutrition and millions of them go to bed hungry especially in the third world counties.

A message from the president

www.maryjosephfoundation.org

The President Favorite Prayer.

2007-08-14T06:54:00.000-07:00

Prayer for God's attentive ear:

And I went on to say: '' Ah, God Almighty the God of the heavens, the God great and fear-inspiring, keeping the covenant and loving-kindness toward those loving you and keeping your commandments, please, let your ear become attentive and your eyes opened, to listen to the prayer of your servant, which I am praying before you today. Nehemiah 1:5,6.

To my sayings do give ear, O God Almighty; Do understand my sighing. Do pay attention to the sound of my cry for help, O my king and my God, because to you I pray. Psalms 5:1,2.

God Almighty the hearer of prayer, to you people of all flesh will come.

www.maryjosephfoundation.org

Alzheimer's the pain and suffering it causes.

2007-08-14T06:09:00.000-07:00

Alzheimer's cost

The national tab for caring for individuals with Alzheimer's disease is estimated at well over $100 billion annually, and worldwide over $ 350 billion annually.

Alzheimer's disease costs U.S. businesses more than $60 billion a year, stemming from lost productivity and absenteeism by primary caregivers, and insurance costs.

The annual cost of caring for one individual with Alzheimer's disease ranges from nearly $18,800 to more than $39,000, depending on the stage of the disease.

Mary Joseph Foundation:
We give Free foods, vitamins, medicines, rooming and provides other cares for individuals who have Alzheimer's and Dementia disease, we provide these free services from donations.

Experiencing Alzheimer's Disease:

I saw my mother suffered for over seven years with Alzheimer's disease in difference stages from getting lost and packing bags with sugar, rice, raw chicken, raw meat and threw all in a old bag with some of her clothes and saying she is leaving, to acting like a little school girl, then seeing her sick down in bed and can't move and groaning and later in the hospital with tubes in her nose, I remember many nights and days I and my sisters cried to see our mother who was so kind, giving and loving especially to others going through this sickness, to see some one you really love going through this sickness that the Doctors call Alzheimer's disease especially you own mother who you really love, then in December 1998 after six weeks in Clara Mass Hospital in Belleville NJ my mother past it was not a good experience to see my mother suffering then later pasting. In 1992 we made promise to our mother to help others especially to those who do not have anything and homeless or in mental disturb homes. In the 90s I lost two cousins and my mother to Alzheimer's disease. We are here to help and all of the Donations are going toward taking care of the people who need it most because we were there and it touch, move us and we feel it and experience it and we are now sharing it with others in a loving way.

A message from the president
Mary Joseph Foundation

F. Joseph president left senior positions at Citi Bank, JP Morgan, IBM and the Federal Government to help peoples in need.

alzheimers@maryjosephfoundation.org

Mary Joseph Foundation Cares About You.

2007-08-12T11:23:00.000-07:00

Police chief has Alzheimer's
Watch interview with chief Johansen.

We are a non-profit organization, our mission for all individuals around the world is '' to provide the best cares and services possible to each individuals confronting dementia and Alzheimer's, and to their families and caregivers.

We know what its like to be families and caregiver of Alzheimer's and dementia patients because the president, vice president and several of the workers at this organization mother Mary and two cousin's Fan and Willie all die from Alzheimer's.

We strongly believe in giving of our times and expertises in caring for every individuals with Alzheimer's and dementia, we always remember '' There are greater happiness in giving than receiving ''

A message from the president.

Alzheimer's disease world-wide.

2007-08-12T10:51:00.000-07:00

We care's

Our main gold is to eliminate Alzheimer's disease through the advancement of research; at the same time to provide and enhance care and support for all affected by this disease; and to reduce the risk of dementia through the promotion of brain health. We are working very hard so that one day there would be a world without Alzheimer's disease, but for now with your donations its allow us to build homes, give medicine, food and remove individuals who have Alzheimer's disease from the street who are homeless and from mental disturb homes and care's for them.

Expert Speakers.

2007-08-12T09:49:00.000-07:00

Speakers on several topics

Speakers:

We have several speakers from the world of politics, religions, medicines and engineering.

Topics on:

Alzheimer's disease. The Bible history and religion. Politics and how its effect you. Network security and you.

Our speakers can come to your place of Business or College and give a talk on any of these topics.

The Mary Joseph Foundation is interested in building a relationships with Companies to help increase awareness of Alzheimer's disease and the world we live in today, we are eager to work with Companies, Colleges and others to explore how the Mary Joseph Foundation can best support your business goals and objectives.

Working with our foundation will helps us to accelerate our mission to eliminate Alzheimer's disease and to provide the best care and support to those living with Alzheimer's world-wide.

Many of our speakers worked for Citi Bank, JP Morgan, IBM, AT&T, Research Centers and government, some of these speakers are Rhodes scholars.

alzheimers@maryjosephfoundation.org

Mary Joseph Foundation

There are more happiness in giving than receiving

2007-08-12T08:49:00.000-07:00

What are we doing now:

We are building homes in the Caribbean and Africa for individuals who have Alzheimer's disease and living on the street and in homes for the mental disturb, many times they are beaten by other who don't understand the sickness, we are trying our best to take care of many of these individuals as possible, we hope to complete several homes within the next year, these homes provide free rooming, medicines, foods and vitamins for these individuals who have Alzheimer's disease.

Email: alzheimers@maryjosephfoundation.org

www.maryjosephfoundation.org

Building Homes for the individuals with Alzheimer's.

2007-08-12T08:42:00.001-07:00